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1. Introduction
The human leukocyte antigen (HLA) system is a cluster of gene complex encoding the major
histocompatibility complex (MHC) proteins known as antigens located on the cell mem-
brane of leukocytes in humans from which its name was derived. The functions of these cell
surface proteins are many like responsible for the regulation of the immune system whether
humoral or cellular in humans. It is the most important area in the vertebrate genome regard-
ing infection and autoimmunity, and is essential in adaptive and innate immunity. The HLA
gene complex is located on a 3-Mbp stretch within short arm of chromosome number 6p21.
HLA genes are codominantly expressed and highly polymorphic, those have many different
alleles that modify the adaptive immune system that helps body to distinguish the body’s
own protein from foreign invaders protein like virus, bacteria, or any other pathogens [1, 2].
1.1. Classification
The antigens of the HLA complex can be classified into three classes: class 1, class 2, and class 3.
1-MHC class I: There are three major and three minor MHC class I genes in HLA.
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• HLA-E
• HLA-F
HLA-G β2-microglobulin binds with major and minor gene subunits to produce a heterodimer.
2-MHC class II: There are three major and two minor MHC class II proteins encoded by the 
HLA.
Major MHC class II:
1. HLA-DP
• α-chain encoded by HLA-DPA1 locus
• β-chain encoded by HLA-DPB1 locus
2. HLA-DQ
• α-chain encoded by HLA-DQA1 locus
• β-chain encoded by HLA-DQB1 locus
3. HLA-DR
• α-chain encoded by HLA-DRA locus
• β-chains (only three possible per person),
They are encoded by HLA-DRB1, DRB3, DRB4, and DRB5 loci.
The genes of the class II combine to form heterodimeric (αβ) protein receptors that are typi-
cally expressed on the surface of antigen-presenting cells.
Minor MHC class II:
• DM
• DO
They are used in the internal processing of antigens, loading the antigenic peptides generated 
from pathogens onto the HLA molecules of antigen-presenting cell [3, 4].
A person’s HLA complex is genetically inherited from their parents (50% from each parent), 
so you are more likely to have stronger matches with your siblings than with a random mem-
ber of the population; however, each pair of siblings still only has a 25% chance of matching 
perfectly. The likelihood of having a perfect match with someone unrelated to you is approxi-
mately 1 in 100,000. Thus, the closer the match between two people like identical twins, the 
less likely the recipient’s immune system will attack the donor’s cells (Figure 1) [5].
Human Leukocyte Antigen (HLA)2
1.2. Structure
1.2.1. MHC class I
MHC class I molecule structure is consisting from two heterodimer polypeptide chains, α and 
β2-microglobulin that linked together noncovalently by interaction of beta-2 microglobulin with 
α3 domain of alpha chain. The alpha chain is encoded by many genes which are highly polymor-
phic, while beta-2 microglobulin subunit is not polymorphic and encoded by genes called beta-2 
microglobulin gene. The other domain is α3 domain which is plasma membrane that interacts with 
CD8 receptor of T-cytotoxic lymphocytes. This α3-CD8 complex holds the MHC I molecule and the 
T-cell receptor (TCR) on the cell surface of the cytotoxic T cell binds its α1-α2 heterodimer and exam-
ines the foreign substance for antigenicity. The two domains, α1 and α2, fold to form a groove or 
basket for antigenic peptides to bind to it which consists of 8–10 amino acid in length (Figure 2) [6].
1.2.2. MHC class II
Class II molecules are also heterodimers in their structure, but consist of two homogenous 
peptides, an α and β polypeptide chain, both of which are encoded in the MHC. The alpha 
chain has two domes which are α1 and α2. Beta polypeptide chain has also two domains, β1 
Figure 1. HLA complex is found on chromosome 6 in humans [5].
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and β2. Every domain is encoded by a diverse exon gene, and other genes contain domains 
that encode different parts (leader sequences, transmembrane sequences, and cytoplasmic 
tail). The α1 and β1 regions of the chains form a membrane peptide binding domain, while the 
α2 and β2 regions form a membrane-proximal immunoglobulin-like domain. The groove or 
basket that binds the antigen or peptide is made up of two α-helix walls and β-sheet. Antigen-
binding groove of MHC class II molecules is open at both ends and the groove on class I 
molecules is closed at each end resulting in antigens that bind to MHC class II molecules 
longer about 15–24 amino acid residues long. These domains are also highly polymorphic 
(Figure 3) [7].
1.3. Function
The major histocompatibility complex is a highly polymorphic region in the human genome 
located on short arm of chromosome number 6 about 200 genes in the region and is directly 
involved with the immune system. This is due to balancing selection acting on many genes 
with recombination in the MHC region [8]. These genes are in association with nonimmu-
nologic genes like noncoding RNA genes, including expressed pseudogenes. MHC genes 
showed haplotype-specific linkage disequilibrium patterns contain the strongest cis- and 
trans-eQTLs/meQTLs in the genome and are called as a hot spot for disease associations. 
Figure 2. Structure of MHC class I.
Human Leukocyte Antigen (HLA)4
The haplotype HLA-DR/DQ is structurally most variable and shows the highest number of 
disease associations. Dependence on a single reference sequence is not easy. Thus, analysis of 
GWAS for the MHC region is needed. One of the several issues with expected GWAS analysis 
is that it does not address this additional layer of polymorphisms unique to the MHC region 
[9]. Genome-wide association studies (GWAS) demonstrated that MHC is an important area 
for disease association, for example, autoimmune diseases [10, 11]. This very high-variety 
and broad-linkage disequilibrium leads to difficulty in assessing the one that leads to dis-
ease development and associations. Genome mapping can be sequence in addition to MHC 
haplotype and genome reference [12–14]. Many methods are defined but they are expensive 
[15–18]. Thus, many alleles of HLA had an association with cancer, infection with microor-
ganisms in addition to its relation with transplant rejection.
1.4. Role of human leukocyte antigens (HLA) in transplantation
Human leukocyte antigens have an important role in graft rejection. One of the important 
squeal of mismatched graft is the development of donor-specific antibodies (DSA), which 
Figure 3. Structure of MHC class II.
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causes antibody-mediated rejection, graft loss, and repeat transplantation in addition to tissue 
typing. These DSA are induced by foreign epitopes present on the leukocytes mismatched 
with HLA antigens of the donor [19]. The presence of pretransplant DSAs in deceased donor 
transplantations is a risk marker for graft loss, whereas nondonor-specific anti-HLA antibod-
ies are not associated with a lower graft survival and sensitized patients with these antibodies 
directed against class I and II may be a risk marker for graft loss in the long term [20]. These 
antibodies develop through pregnancy, blood transfusions, or organ transplants. After viral 
infection or vaccination, antibodies produced may have the capacity to cross-react with HLA 
called heterologous immunity caused by T-cell alloreactivity or by bystander activation of 
dormant HLA-specific memory B cells [21].
1.5. Human leukocyte antigen and disease association
HLA had an important role in immunopathogenesis of many diseases. The strongest associa-
tion is HLA-B27 and ankylosing spondylitis. There is a long list of diseases associated with 
HLA. Bullous pemphigoid is the most common autoimmune blistering disease and is due to 
IgG recognition of two hemidesmosomal antigens, that is, BP230 (BP antigen 1) and BP180 
(BP antigen 2, collagen XVII). The role of HLA-DQB1*03:01 binding to the immunogenic por-
tion of BP180 provides a potential mechanism by which exposure to neuronal collagen BP180 
may lead to cutaneous disease. Patients who have allele HLA-DQB1*03:01 had an increased 
T-cell avidity to many epitopes like BP180-NC16a domain. Patients with Th1/Th2 imbalance, 
anergy is absent and T-cells are subsequently primed end in autoimmunity against the BP180-
NC16a domain and disease development [22]. Type 1 diabetes patients are more liable to 
develop celiac disease because these two diseases are associated with DQB1 *02:01 and DQB1 
*03:02 and the patients with coexisting T1 diabetes and celiac disease had an HLA profile 
more similar to T1D patients than CeD patients [23].
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Abstract
Early-onset (pediatric and adolescent) multiple sclerosis (MS) is a chronic autoimmune 
and neurodegenerative disorder of the central nervous system, which accounts for 3–5% 
of all MS cases. The major histocompatibility complex (MHC) with its polymorphisms 
has been the genetic locus with the most robust association with adult MS, since its first 
discovery in the 1970s. Nowadays, human leukocyte antigen (HLA) typing studies and 
genome-wide association studies (GWAS) have tried to provide insight into the genetics 
of early-onset MS and their role in disease diagnosis, prognosis, and therapeutic decision-
making. Fundamental genetic similarities have emerged, supporting the assumption that 
MS shares similar genetic variants and biological processes in all age groups. In this chap-
ter, we considered it useful to collect all the available data concerning the HLA distribu-
tion in early-onset MS, given the absence of a review paper with such an approach. We 
additionally aimed toward the summarization of the association of the HLA frequencies in 
early-onset MS and the main acquired demyelinating disorders that are considered in dif-
ferential diagnosis of early-onset MS, like ADEM, NMO/NMOSD, and anti-MOG encepha-
lopathy, for further understanding and current or future research in this promising field.
Keywords: multiple sclerosis, pediatric, early onset, human leukocyte antigens, 
immunogenetics, therapy, precision medicine
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Early-onset (pediatric and adolescent) multiple sclerosis (MS), which accounts approximately 
for 3–5% of all MS cases worldwide, has recently aroused the interest of the scientific com-
munity regarding its underlying pathogenetic mechanisms, both autoimmune demyelination 
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specific age, other acquired demyelinating diseases are in the MS differential diagnosis of 
everyday practice, like ADEM, anti-MOG encephalopathy, and optic neuritis [4]. Recently, 
anti-NMO, anti-MOG, and other autoantibodies have been established as strong biomarkers 
of the previously referred newly emerged clinical entities or a key element of classical demy-
elinating diseases, like MS, especially of early onset [5, 6].
Nevertheless, for four decades now, the HLA alleles have been globally recognized as the core 
genetic (risk or protective) component in adult MS. Since the early 1970s, the major histocom-
patibility complex (MHC) with its polymorphisms on chromosome 6p21.3 [7, 8] has been the 
genetic locus with the most robust association with MS. In specific, DRB1*1501 (split of DR2), 
along with DRB1*0301 and DRB1*1301, has been found to confer risk for MS, while HLA-
A*0201 protection against MS [9]. Genome-wide association studies (GWAS) regarding early-
onset MS are still ongoing, in contrast with large-scale cohorts of adult-onset MS patients. 
However, single nucleotide polymorphisms (SNPs) of more modest effect have been detected 
that influence the risk of both adult- and early-onset MS, equalizing the genetic burden of 
these age groups [10–12]. The HLA alleles that have been studied in early-onset MS concern 
mainly the class II DRB1* and DQB1* loci, although DPB1* alleles confer susceptibility in 
adult-onset MS as well [13]. Thus, HLA immunogenetics in early-onset MS apart from the 
lower number of worldwide studies needs an extension to the whole HLA class I and class 
II systems, given the increased role that was in MS risk and MS association with vitamin D, 
body mass index (BMI), hormones, estrogen receptor, gender, EDSS score, disease course, 
MRI findings, cognitive status, and most importantly neutralizing antibody formation and 
response to treatment [8, 14–18].
In this chapter, we present the available data concerning the HLA distribution in early-onset 
MS, in parallel with the other acquired demyelinating diseases, given the increased knowl-
edge that has recently emerged in this promising field. We also aimed to include all this useful 
data in a workable table.
2. HLA allele distribution in early-onset MS worldwide
Regarding HLA alleles, DRB1*15 association with early-onset MS has been noted by a series 
of studies [12, 19–22]. In 2000, a study of 286 Norwegians MS patients demonstrated that the 
HLA-DR2, DQ6 haplotype is negatively correlated with age at diagnosis [23]. Since then, 
many studies came to show that DRB1*15-positive patients have a significantly earlier age at 
onset than DRB1*15-negative patients [18, 24–30]. Maslova et al. replicated this testimony in 
a pure pediatric Russian population in 2000 [31]. An Australian study of 978 patients in 2010 
went further to prove that carrying DRBI*15 significantly decreases the age of MS onset by 
3.2 years in homozygotes and 1.3 years in heterozygotes [32].
On the other hand, a series of studies pleads against these remarks and claims no correlation 
of DRB1*15 status and age of disease onset [33–39]. In a Korean population, close linkage of 
DRB3*02, DRB1*13, and DQB1*03 was also associated with the risk of childhood MS, while 
DRB1*1501 was not as high as in Western children [40].
Human Leukocyte Antigen (HLA)10
A remarkable DRB1-genotyping study in Australia in 2010 declared the first results indica-
tive of the significance of the epistatic interactions at the HLA-DRB1 locus. Carriage of 
the DRB1*1501 risk allele alone was not significantly associated with age at disease onset, 
while the DRB1*0401 allele was associated with a reduced age at onset when combined with 
DRB1*1501 [41].
Regarding Greece, Anagnostouli et al. in 2003 noticed for the first time the higher frequency 
of DRB1*1501 in MS patients [42]. In 2011, Kouri et al. [43] observed no significant correlations 
among DRB1*1501, DQB1*0602, and DQA1*0102 alleles with age at onset, an observation 
repeated by Anagnostouli et al. in 2014 [20]. Anagnostouli et al. attributed this discrepancy 
either to a possible parent of origin effect, relying on Ramagopalan et al.’ observation that 
only maternally transmitted DRB1*15 promotes a lower age of MS [44], or to fluctuations 
of vitamin D levels among different populations [45]. New findings in this former are the 
putative predisposing role of DRB1*03 allele and the protective role of the DRB1*16 allele for 
early-onset MS [20].
While the role of HLA alleles in early-onset MS has been well studied, this is not the case in 
other young-onset acquired demyelinating diseases, especially acute disseminated encepha-
lomyelitis (ADEM) and neuromyelitis optica (NMO), its main differential diagnoses. In 
Table 1, we summarize the available data regarding the HLA allele distribution in early-onset 
MS, ADEM, and NMO, and despite the obvious lack of information, the primary results dem-
onstrate clear genetic diversity [12, 18–41, 46–49].
3. Conclusions
The well-established HLA-DRB1*15:01 allele associated with adult-onset MS appears to confer 
increased susceptibility to early-onset MS too, supporting a fundamental similarity in genetic 
contribution to MS risk, regardless of age at onset. Regarding whether HLA-DRB1*1501 by itself 
lowers the age at onset of MS, the results are conflicting and possibly related to both genetic and 















HLA-DRB1*01 and HLA-DRB1*017 
(Russian)
HLA-DRB1*1501 and HLA-DRB5*0101 
(Korean)
HLA-DQB1*0602, HLA-DRB1*1501, and 
HLA-DRB1*1503 (Brazil)
HLA-DRB1*16 and HLA-DQB1*05 
(Caucasian adult)
MS, multiple sclerosis; ADEM, acute disseminated encephalomyelitis; NMO, neuromyelitis optica.
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HLA-DRB1*04 also appears to bind with high affinity to myelin oligodendrocyte glycoprotein 
(MOG) epitopes, whose role in early-onset demyelinating disorders has been widely studied, 
in both familial MS patients and asymptomatic relatives, indicating that the humoral immune 
reactivity against MOG is partially under control of certain HLA class II alleles [50–54]. This 
observation could guide therapy, as HLA-DRB1∗0401 allele is associated with greater risk of 
developing neutralizing antibodies against interferon beta (IFN-𝛽𝛽) in adult studies, resulting 
in poorer therapeutic outcome [55]. Finally, the putative relation of DRB1*03 allele with early-
onset MS is also interesting, as this allele has been associated not only with a presumed better 
MS prognosis but also with NMO [46], a mainly humoral immunological entity.
Accumulating data highlights the role of HLA-genotype and especially HLA-DRB1*1501 in 
regulating the immune response to a range of environmental factors, modulating the risk 
of MS appearance. Research has mainly focused on viral infections, especially EBV [56–58], 
CMV, and HSV-1 [58]. In specific, Epstein–Barr nuclear antigen-1 seropositivity has been asso-
ciated with an increased risk of MS, while a remote infection with CMV with a lower risk. A 
strong interaction has been found between HSV-1 status and HLA-DRB1 in predicting MS, as 
HSV-1 has been associated with an increased risk of MS only in DRB1*15 carriers. Moreover, 
obesity and higher body mass index (BMI) during adolescence, rather than childhood, seem 
to be critical in determining MS risk [59], while tobacco smoke exposure and HLA-DRB1*15 
interact to increase risk for MS in children diagnosed with monophasic acquired demyelinat-
ing syndromes [60]. Finally, as research regarding the role of gut bacteria in the development 
of central nervous demyelinating disorders robustly expands, possible protective correlations 
of specific bacteria through interplay with specific HLA alleles emerge in animal models of 
MS, expanding our knowledge regarding disease pathogenesis [61, 62]. Larger studies in 
early-onset MS populations are required in order to clarify these possible correlations which 
may also expand to other HLA alleles, proving the interplay among cellular activity, humoral 
activity, and environment in MS and their possible impact in therapeutics.
In conclusion, HLA alleles emerge as a primary biomarker in both early- and adult-onset MS, 
regarding genetic risk, outcome, and differential diagnosis. We strongly believe that larger 
HLA-genotyping studies regarding early-onset demyelinating disorders are needed, in dif-
ferent ethnic groups, in order to clarify, replicate, and expand the already limited existing 
results. We also believe that these future studies will aim toward personalized therapeutics 
and generally precision medicine in early-onset MS patients.
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in both familial MS patients and asymptomatic relatives, indicating that the humoral immune 
reactivity against MOG is partially under control of certain HLA class II alleles [50–54]. This 
observation could guide therapy, as HLA-DRB1∗0401 allele is associated with greater risk of 
developing neutralizing antibodies against interferon beta (IFN-𝛽𝛽) in adult studies, resulting 
in poorer therapeutic outcome [55]. Finally, the putative relation of DRB1*03 allele with early-
onset MS is also interesting, as this allele has been associated not only with a presumed better 
MS prognosis but also with NMO [46], a mainly humoral immunological entity.
Accumulating data highlights the role of HLA-genotype and especially HLA-DRB1*1501 in 
regulating the immune response to a range of environmental factors, modulating the risk 
of MS appearance. Research has mainly focused on viral infections, especially EBV [56–58], 
CMV, and HSV-1 [58]. In specific, Epstein–Barr nuclear antigen-1 seropositivity has been asso-
ciated with an increased risk of MS, while a remote infection with CMV with a lower risk. A 
strong interaction has been found between HSV-1 status and HLA-DRB1 in predicting MS, as 
HSV-1 has been associated with an increased risk of MS only in DRB1*15 carriers. Moreover, 
obesity and higher body mass index (BMI) during adolescence, rather than childhood, seem 
to be critical in determining MS risk [59], while tobacco smoke exposure and HLA-DRB1*15 
interact to increase risk for MS in children diagnosed with monophasic acquired demyelinat-
ing syndromes [60]. Finally, as research regarding the role of gut bacteria in the development 
of central nervous demyelinating disorders robustly expands, possible protective correlations 
of specific bacteria through interplay with specific HLA alleles emerge in animal models of 
MS, expanding our knowledge regarding disease pathogenesis [61, 62]. Larger studies in 
early-onset MS populations are required in order to clarify these possible correlations which 
may also expand to other HLA alleles, proving the interplay among cellular activity, humoral 
activity, and environment in MS and their possible impact in therapeutics.
In conclusion, HLA alleles emerge as a primary biomarker in both early- and adult-onset MS, 
regarding genetic risk, outcome, and differential diagnosis. We strongly believe that larger 
HLA-genotyping studies regarding early-onset demyelinating disorders are needed, in dif-
ferent ethnic groups, in order to clarify, replicate, and expand the already limited existing 
results. We also believe that these future studies will aim toward personalized therapeutics 
and generally precision medicine in early-onset MS patients.
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Abstract
In the field of organ transplantation, donor-specific anti-HLA antibodies (DSA) have 
gained more popularity, as antibody-mediated rejection (AMR) has been recognized 
as an important factor to determine allograft survival. Thus, it is reasonable to believe 
that appropriate control of DSA is directly linked to well-managed immunosuppression, 
resulting in free from AMR. First, in order to prevent and manage AMR, it is of vital 
importance to be familiar with updated knowledge regarding crossmatch test and DSA 
detection methods, including intra-graft DSA. Second, it is also crucial to understand 
the standard criteria to diagnose AMR. Although pathological diagnosis and serum 
DSA (s-DSA) detection play the central role, the recent trend seems to be detection of 
intra-graft DSA (g-DSA). Third, regarding organ transplantation between sensitized 
pairs, the acceptable outcomes are obtained owing to recent preoperative desensitization 
protocols: depletion/modification of B cells, apheresis for antibodies, and inhibition of 
reaction between DSA and HLA. Finally, we would like to discuss the treatment of AMR. 
Further advances in diagnosis methods and emergences of effective treatments would be 
expected for acceptable control of AMR. In this chapter, we will review from the basics to 
recent topics in order to understand DSA and AMR.
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1. Introduction
Recent advances in immunosuppression permit for organ transplantation between sensitized 
recipients and donors with acceptable outcomes. However, it is true that the management 
of acute or, in particular, chronic antibody-mediated rejection (AMR) due to donor-specific 
anti-HLA antibodies (DSA) is still a crucial issue to improve long-term graft survival. Because 
chronic changes of AMR are irreversible, it is also true that an early accurate diagnosis of AMR 
is required to prevent severe consequences. Thus, it is reasonable to believe that DSA is a main 
research topic to improve the outcome of organ transplantation. In the 1960s, the introduction 
of azathioprine brought the beginning of contemporary organ transplantation [1]. Following 
this era, incompatibilities, anti-AB [2, 3] and anti-HLA antibodies [4], were recognized as a 
crucial barrier for organ transplantation. In the next half-century, the main attention was paid 
to cellular rejection: T-cell-mediated rejection [5]. This resulted in the development of calci-
neurin inhibitors [6] and several antibody drugs [7]: a depletion of lymphocytes that enabled 
the control of T-cell-mediated rejection. However, AMR remains an important issue that is 
still not addressed. Then, DSA have finally received strong attention in the twenty-first cen-
tury because DSA are important factors to determine long-term graft survival. In this chapter, 
we will review DSA in organ transplantation and discuss effectiveness of a novel application 
of immunocomplex capture fluorescence analysis (ICFA), as well as crossmatch examinations, 
protocols of desensitization, and outcomes of crossmatch positive organ transplantation.
2. Assessment for donor-specific anti-HLA antibodies
To assess reactive DSA in recipient serum, a crossmatch test or measurement of DSA is per-
formed routinely in clinical organ transplantation. There are several crossmatch methods: 
lymphocyte cytotoxic test (LCT), flow cytometry crossmatch (FCXM), and ICFA. In addition 
to crossmatch test, antibody detection methods such as flow PRA screening and single anti-
gen bead assay (SAB) are utilized in clinical settings. Generally, it is important to understand 
the advantages and disadvantages of these methods and interpret appropriately.
2.1. Lymphocyte cytotoxic test
Antigen–antibody and complement-dependent reactions are observed in this traditional 
direct-crossmatch test. Donor lymphocytes are incubated in the recipient serum, followed by 
the addition of complements. Under the circumstances where there are DSA in the recipient 
serum, lymphocytes are necrotized by the complement-dependent cytotoxicity reaction. Then, 
adding eosin dye, the ratio of necrotized lymphocytes is counted by a phase-contrast micros-
copy (Figure 1). The disadvantages of LCT are relatively low sensitivity, difficulty in obtaining 
donor alive lymphocytes, and subjective judges. Furthermore, it should be noted that some-
times non-DSA reaction can be observed. Conversely, only this traditional method is capable 
of visualizing real reactions against donor cells, including non-DSA reactions [8]. Thus, it is 
true that careful attention should be paid when positive reaction in LCT is detected [9].
Human Leukocyte Antigen (HLA)20
2.2. Flow cytometry crossmatch
FCXM is an examination that flow cytometry technology is applied. As characteristics of 
FCXM test, sensitivity is high enough to detect a slight amount of DSA. Therefore, it should 
be paid attention that non-HLA antibodies might be detected: false positive. Because of high-
sensitivity examination, rigorous quality control is required. To apply FCXM, donor lympho-
cytes and recipient serum samples were utilized. Subsequently, antihuman IgG antibodies are 
added and positivity is determined [10]. In addition, to add CD3 or CD19, T cells and B cells 
can be separated and analyzed simultaneously (Figure 2).
2.3. Immunocomplex capture fluorescence analysis
WAKFlow HLA antibody class I and II ICFA (Wakunaga Pharmaceutical Co., Ltd., Osaka, 
Japan) is one of the crossmatch tests by using donor lymphocytes and recipient serum [11]. 
This technique can detect DSA immunocomplex with high specificity [12]. As a detection 
system, Luminex xMAP technology (Luminex Corporation, Austin, TX) is applied. Schematic 
presentation of ICFA is shown in Figure 3. First, HLA and DSA complexes are formed follow-
ing the reaction between donor lymphocytes and recipient serum containing DSA. Second, 
lymphocytes are lysed and complexes remain in lysates. Third, these complexes are captured 
by anti-HLA monoclonal antibodies fixed on Luminex beads, and subsequently PE-conjugated 
human anti-IgG is added. Finally, Luminex system detects these PE-conjugated anti-human 
Figure 1. Lymphocyte cytotoxicity test (LCT). (a) Schematic presentation of LCT. (b) Representative results of 
LCT. Necrotized lymphocytes were stained in black by eosin dye. Negative reaction (grade 1–2) and positive reaction 
(grade 4–8).
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IgG signals. As ICFA characteristics, the following features are noted: (1) the specificity of 
identifying HLA antibodies is high, and (2) class I and II antibodies can be identified sepa-
rately. Furthermore, in terms of recent advances in ICFA, DR, DQ, and DP, DSA can be identi-
fied separately.
2.4. FlowPRA screening
To identify anti-HLA antibodies in serum, FlowPRA screening test is performed. First, a reac-
tion is caused between anti-HLA antibodies and latex beads coated with HLA antigens. Then, 
Figure 2. Flow cytometry crossmatch (FCXM). (a) Schematic presentation of FCXM. (b) an example of positive reaction 
by non-HLA antibodies. (c), (d) representative results of FCXM using T cell (c) or B cell (d).
Figure 3. Schematic presentation of immunocomplex capture fluorescence analysis (ICFA).
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FITC-conjugated antihuman IgG is added. Subsequently, mean fluorescence intensity (MFI) 
and shift from negative control are calculated based on flow cytometry analyses (Figure 4). 
Each mixed class I and II HLA antigen is separately coated on latex beads, derived from about 
30 types of panel cells [13]. Depending on the human race, there is a possibility that rare HLA 
Figure 4. FlowPRA screening. (a) Schematic presentation of FlowPRA screening. (b) Examples of positive FlowPRA 
screening results about class I (upper) and class II (lower).
Figure 5. Schematic presentation of single antigen bead assay (SAB).
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antigens are not covered. These disadvantages should be recognized. Generally, if a positive 
reaction would be observed, the following SAB is applied to identify the specificity of anti-
HLA antibodies.
2.5. Single antigen bead assay
To identify the specificity of anti-HLA antibodies, SAB is performed when crossmatch test 
and/or FlowPRA is positive. First, a reaction is observed between anti-HLA antibodies 
and Luminex beads coated with a single HLA antigen extracted from gene-modified cells. 
Following steps are similar to those of FCXM. Finally, these reactions, MFI of PE signals, were 
calculated by Luminex system (Luminex Corporation). According to HLA typing of donor, 
the presence of DSA is judged. It is often used in LABScreen single antigen HLA class I/II 
beads: LABScreen single antigen class I/LABScreen single antigen class II (One Lambda Inc., 
Canoga Park, CA) or WAKFlow HLA antibody class I HR and WAKFlow HLA antibody class 
II HR (Wakunaga Pharmaceutical Co., Ltd) (Figure 5). As an important point, because these 
single HLA antigen beads do not include all types of HLA antigens, we should be familiar 
with SAB kit to judge the existence of DSA appropriately.
3. Assessment for intra-graft donor-specific anti-HLA antibodies
Due to recent advances in examinations for DSA, the assessment for g-DSA has been paid atten-
tion. In fact, it is hard to understand that s-DSA damage allografts without localization in target 
organs. Thus, hereafter, the assessment of g-DSA would gain more popularity as diagnosis or 
prognosis factors. Although the presence of g-DSA is not included in AMR diagnosis criteria 
currently, g-DSA might be a key criterion for considering AMR in the near future. It would be 
better that clinicians and researchers are aware of this novel topic. Here, we will present rep-
resentative two different methods. We will also delve into graft ICFA technique in this section.
3.1. Dissociation between HLA and DSA (acid elution method)
To obtain free DSA from allografts, dissociation HLA and DSA complexes are attempted. 
So far, g-DSA detection in the kidney [14–16], liver [17], and lung [18] were reported. This 
method requires the following steps: (1) Wash more than seven times to prevent from detec-
tion s-DSA incorrectly. (2) Dissociate these complexes by acid (buffer). (3) Detect dissociated 
DSA by SAB (Figure 6). As compared to graft ICFA, mentioned later, acid elution method 
has weak points regarding simplicity and remains doubtful points whether DSA denature 
or not during the acid elution step. However, SAB analysis following acid elution seems to 
be accepted widely and allows to identify specific DSA even where multiple candidate DSA 
exist. The common recognition of g-DSA assessment seems to be that g-DSA is an important 
factor to determine graft survival and more sensitive than s-DSA [14].
3.2. Graft immunocomplex capture fluorescence analysis (non-dissociation 
technique)
WAKFlow HLA antibody class I and II ICFA is an attractive tool to identify HLA/DSA com-
plexes as mentioned above, by means of WAKFlow HLA antibody class I and II (Wakunaga 
Human Leukocyte Antigen (HLA)24
Pharmaceutical). It is not only for serum of recipients but also for allograft specimens. The 
first graft ICFA was introduced as an effective tool for detection of g-DSA in 2017 [19, 20]. 
Graft ICFA can be performed as previously described by Nakamura et al. Graft samples were 
obtained by means of a percutaneous needle biopsy. To standardize the results of graft ICFA, 
2 mm specimen was used for each analysis. Regarding graft ICFA to identify HLA expres-
sion, samples were washed enough in PBS. As compared to acid elution method of DSA from 
grafts associated to g-DSA detection by SAB, graft ICFA does not allow to identify individual 
responsible HLA alleles, such as HLA-A24, etc. However, in the setting of real organ trans-
plantation, generally HLA alleles are identified prior to transplantation. Thus, it does not 
seem to be difficult to narrow down candidate HLA. It is true, therefore, that current graft 
ICFA is clinically useful to diagnose AMR. Moreover, the combination of acid elution method 
and graft ICFA allows to obtain useful information regarding g-DSA. Further advances in 
graft ICFA would be expected.
(Ethics Committee approval was obtained from the internal research ethics committee of Kyoto 
Prefectural University of Medicine. The clinical trial registration number is UMIN000023787.)
3.3. Data interpretation
MFI of samples was calculated by the Luminex system. A ratio of sample MFI/blank beads 
MFI of all negative samples, including HLA matched recipients’ samples, + 2SD is demon-
strated below 0.9 (data not shown) (please refer to [19, 20]). Then the ratio was determined, 
and ≥ 1.0 was considered as a positive result. Furthermore, to compensate baseline reaction, 
the following index was also calculated. Index = (XHLA-(NHLA-NBB)XBB/NBB)/XBB: XHLA, sample 
Figure 6. The flowchart of the acid elution method (dissociation technique).
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MFI; XBB, sample blank beads MFI; NHLA, the mean MFI of negative samples; and NBB, the 
mean blank beads MFI of negative samples. Given the results of negative samples, the index 
≥1.5 was considered as a positive result.
3.4. DSA-HLA complexes in the liver, heart, lungs, pancreas, and small intestine are 
also successfully detected by graft ICFA
To confirm whether graft ICFA can be applied to other organs besides the kidney [19, 20], 
we employed ten liver transplant recipients and a liver transplant recipient who underwent 
autopsy due to primary graft dysfunction. Samples of other possible organs such as the heart, 
lung, pancreas, and small intestine from this patient were pretreated according to the graft ICFA 
preparation method. Contaminated blood cells in samples were minimum, confirmed by his-
tology. Luminex analyses detected PE signals from the positive control samples in all organs. 
Thus, it can be concluded that graft ICFA can be applied for all organ transplantation (Figure 7).
3.5. Sensitivity and specificity of graft ICFA to determine pathological AMR in renal 
transplantation
In order to prove a hypothesis—graft ICFA is useful to detect g-DSA and AMR—a total of 
40 Japanese renal transplant recipients were included prospectively. They underwent graft 
biopsy and were examined by graft ICFA as previously described [19, 20]. According to the 
results of graft ICFA, these patients were divided into the g-DSA+ and g-DSA- groups to assess 
Figure 7. Intra-graft DSA (g-DSA) in all possible allografts can be analyzed by graft ICFA.
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the sensitivity and specificity of graft ICFA to predict pathological AMR. In the current study, 
this technique has demonstrated 100% sensitivity (12/12) and 92.9% specificity (26/28). Thus, 
it is reasonable to believe that positive graft ICFA results strongly suggest the onset of AMR.
4. Diagnosis of antibody-mediated rejection
4.1. Renal transplantation
With renal allograft dysfunction, it can be diagnosed as AMR, provided that C4d deposited 
in peritubular capillaries (ptc) and antibodies or complement deposition are confirmed in 
vascular fibrinoid necrosis, in addition to s-DSA detection. Recently, AMR can be diagnosed 
according to the Banff classification 2015 [21].
Acute AMR:
The following three criteria should be met when acute AMR is diagnosed:
1. Histological features of acute tissue injury, including at least one of the following
• Microvascular inflammation g > 0 (excluding recurrent or de novo glomerulonephritis), 
ptc > 0, or v > 0 (intimal/transmural arteritis).
• Acute thrombotic microangiopathy (without any other apparent reasons).
• Acute tubular injury (without any other apparent reasons).
2. Histological features due to DSA and vascular endothelium reaction
• Linear C4d deposition in ptc (C4d2 or C4d3 (frozen sections)/C4d > 0 (paraffin embed-
ded sections))
• Moderate microvascular inflammation g + ptc ≥ 2.
• Detection of genetic transcript expression in biopsy specimens due to endothelial injury.
3. Detection of s-DSA
Chronic AMR:
The following three criteria have to be met:
1. Histological features of chronic tissue injury, including at least one of the following
• Transplant glomerulopathy (cg > 0), in the case of no chronic thrombotic microangiopa-
thy, includes histologic features detected by electron microscope (EM).
• Severe ptc basement membrane multilayering by EM.
• New onset of arterial intimal fibrosis (without any other apparent reasons).
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tology. Luminex analyses detected PE signals from the positive control samples in all organs. 
Thus, it can be concluded that graft ICFA can be applied for all organ transplantation (Figure 7).
3.5. Sensitivity and specificity of graft ICFA to determine pathological AMR in renal 
transplantation
In order to prove a hypothesis—graft ICFA is useful to detect g-DSA and AMR—a total of 
40 Japanese renal transplant recipients were included prospectively. They underwent graft 
biopsy and were examined by graft ICFA as previously described [19, 20]. According to the 
results of graft ICFA, these patients were divided into the g-DSA+ and g-DSA- groups to assess 
Figure 7. Intra-graft DSA (g-DSA) in all possible allografts can be analyzed by graft ICFA.
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the sensitivity and specificity of graft ICFA to predict pathological AMR. In the current study, 
this technique has demonstrated 100% sensitivity (12/12) and 92.9% specificity (26/28). Thus, 
it is reasonable to believe that positive graft ICFA results strongly suggest the onset of AMR.
4. Diagnosis of antibody-mediated rejection
4.1. Renal transplantation
With renal allograft dysfunction, it can be diagnosed as AMR, provided that C4d deposited 
in peritubular capillaries (ptc) and antibodies or complement deposition are confirmed in 
vascular fibrinoid necrosis, in addition to s-DSA detection. Recently, AMR can be diagnosed 
according to the Banff classification 2015 [21].
Acute AMR:
The following three criteria should be met when acute AMR is diagnosed:
1. Histological features of acute tissue injury, including at least one of the following
• Microvascular inflammation g > 0 (excluding recurrent or de novo glomerulonephritis), 
ptc > 0, or v > 0 (intimal/transmural arteritis).
• Acute thrombotic microangiopathy (without any other apparent reasons).
• Acute tubular injury (without any other apparent reasons).
2. Histological features due to DSA and vascular endothelium reaction
• Linear C4d deposition in ptc (C4d2 or C4d3 (frozen sections)/C4d > 0 (paraffin embed-
ded sections))
• Moderate microvascular inflammation g + ptc ≥ 2.
• Detection of genetic transcript expression in biopsy specimens due to endothelial injury.
3. Detection of s-DSA
Chronic AMR:
The following three criteria have to be met:
1. Histological features of chronic tissue injury, including at least one of the following
• Transplant glomerulopathy (cg > 0), in the case of no chronic thrombotic microangiopa-
thy, includes histologic features detected by electron microscope (EM).
• Severe ptc basement membrane multilayering by EM.
• New onset of arterial intimal fibrosis (without any other apparent reasons).
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2. Histological features due to DSA and vascular endothelium reaction
• Linear C4d deposition in PTC (C4d2 or C4d3(frozen sections)/C4d > 0 (paraffin embed-
ded sections))
• Moderate microvascular inflammation g + ptc ≥ 2.
• Detection of genetic transcript expression in biopsy specimens due to endothelial injury.
3. Detection of serum DSA
Figure 8. Histopathological impacts of g-DSA presence. A. The Banff histologic scores are analyzed individually based 
on the g-DSA status: G-DSA- or g-DSA+. B. The Banff histologic scores based on the g-DSA status: G-DSA- or g-DSA+ 
without ABO-incompatible cases. C. These items are reanalyzed depending on g-DSA values: G-DSA-, g-DSA < 10, and 
g-DSA ≥ 10, including ABO-incompatible cases. ****p < 0.0001, ***p < 0.0005, **p < 0.005, and *p < 0.05.
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4.1.1. The presence of g-DSA (graft ICFA) is associated with microvascular lesions in renal 
transplantation
To confirm the consistency of graft ICFA results, the individual scores of the Banff classifi-
cation were analyzed between g-DSA- and g-DSA+ renal transplant recipients (g-DSA+ 15, 
g-DSA- 25 recipients). As a result, individual g, cg, ptc, and ptc-bm scores were significantly 
higher in g-DSA+ patients. Interestingly, there was no apparent difference in the C4d stain-
ing score, primarily due to the presence of ABO-incompatible cases in both groups (32.0% 
and 33.3% in the g-DSA- and + groups, respectively) (Figure 8A). Thus, ABO-incompatible 
cases were removed from both groups. Then, the C4d result showed that 0.45 ± 0.17 and 
1.73 ± 0.33 in the g-DSA- and g-DSA+ groups, respectively (p = 0.0184) (Figure 8B). Next, 
g-DSA+ patients were divided into low g-DSA group, g-DSA+ < 10, and high g-DSA group, 
g-DSA+ ≥ 10. Then, this result demonstrated that g and ptc deteriorated in g-DSA concentra-
tion manner. In contrast, only g-DSA+ ≥ 10 group showed significant higher scores in cg, 
mm, ptc-bm, and C4d (Figure 8C). These results might indicate that g-DSA causes microcir-
culation lesions and high g-DSA means chronic allograft damages. To correspond to a recent 
functional concept, g + ptc (microvascular inflammation), g + cg + ptc (microvascular lesions), 
and cg + mm (microvascular deterioration), we also analyzed these scores again. Expectedly, 
g + ptc and g + cg + ptc deteriorated stepwise according to g-DSA scores, but cg + mm referring 
chronic lesions is clearly higher only in the g-DSA ≥ 10 group (Figure 9). It is true, therefore, 
that g-DSA assessment by graft ICFA accurately supports the diagnosis of AMR.
4.2. Liver transplantation
Generally, it is often discussed that liver allografts tend to be resistant against AMR due to 
Kupffer cell DSA clearance, HLA expression in microvasculature, allografts size, and regen-
erative capacity of the liver. Diagnosis criteria are suggested in the Banff meeting [22].
Define acute AMR:
The following four criteria should be met to diagnose acute AMR:
1. Histological features of acute tissue injury, including at least one of the following
Portal microvascular endothelial cell hypertrophy, eosinophilic and neutrophilic portal 
microvasculitis, portal edema, and ductular reaction; cholestasis is usually present but 
variable; edema and periportal hepatocyte necrosis, active lymphocytic, and/or necrotiz-
ing arteritis.
2. Positive s-DSA.
3. Diffuse microvascular C4d staining (C4d = 3).
4. Excluding other lesions possibly mimic AMR.
Suspicious for AMR (both criteria required).
Serum DSA + and positive histopathology score (h-score) (C4d + h-score ≥ 3).
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2. Histological features due to DSA and vascular endothelium reaction
• Linear C4d deposition in PTC (C4d2 or C4d3(frozen sections)/C4d > 0 (paraffin embed-
ded sections))
• Moderate microvascular inflammation g + ptc ≥ 2.
• Detection of genetic transcript expression in biopsy specimens due to endothelial injury.
3. Detection of serum DSA
Figure 8. Histopathological impacts of g-DSA presence. A. The Banff histologic scores are analyzed individually based 
on the g-DSA status: G-DSA- or g-DSA+. B. The Banff histologic scores based on the g-DSA status: G-DSA- or g-DSA+ 
without ABO-incompatible cases. C. These items are reanalyzed depending on g-DSA values: G-DSA-, g-DSA < 10, and 
g-DSA ≥ 10, including ABO-incompatible cases. ****p < 0.0001, ***p < 0.0005, **p < 0.005, and *p < 0.05.
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variable; edema and periportal hepatocyte necrosis, active lymphocytic, and/or necrotiz-
ing arteritis.
2. Positive s-DSA.
3. Diffuse microvascular C4d staining (C4d = 3).
4. Excluding other lesions possibly mimic AMR.
Suspicious for AMR (both criteria required).
Serum DSA + and positive histopathology score (h-score) (C4d + h-score ≥ 3).




1. C4d + h-score ≥ 2.
2. DSA and C4d immunohistochemistry not available and not apparent.
3. Coexisting pathophysiology might cause similar injury.
Liver allograft chronic active AMR is also considered as an important factor for determining 
long-term outcome [23, 24]. Chronic active AMR is diagnosed when the condition meets the 
all following criteria:
1. Histologic features consistent with chronic active AMR. (a) At least mild mononuclear por-
tal and/or perivenular inflammation with interface and/or perivenular necroinflammatory 
activity. (b) At least portal/periportal, sinusoidal, and/or perivenular fibrosis.
Figure 9. G-DSA effects on the functional clusters of the Banff classification. The functional clusters, g + ptc (microvascular 
inflammation), g + cg + ptc (microvascular lesions), and cg + mm (microvascular deterioration), are analyzed according 
to the presence or absence of g-DSA (A) and g-DSA values: G-DSA-, g-DSA < 10, and g-DSA ≥ 10 (B). ****p < 0.0001 and 
*p < 0.05.
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2. Detection of serum DSA.
3. Focal C4d deposition in portal tract microvascular endothelia (> 10%).
4. Other lesions can be denied.
4.3. Heart transplantation
Following heart transplantation, the onset of AMR is generally estimated around 10–20% 
[25]. In the field of heart transplantation, AMR is also considered as an important prognosis 
factor. In fact, the consequences are severe, and the development of cardiac allograft vas-
culopathy (CAV) has a huge impact. As with other organ transplantations, timing of AMR 
onset is diverse: both acute AMR within 1 week after transplantation and chronic AMR in 
the remote period can be seen. Again, allograft biopsy also plays a crucial role to accurately 
diagnose AMR. Repeated allograft biopsies seem to be required for achieving good long-term 
outcomes. Interestingly, regarding de novo DSA synthesized after 2 months following heart 
transplantation, class II DSA are dominant [25].
Diagnosis criteria of heart allograft AMR were discussed in the international society for heart 
and lung transplantation working formulation consensus [26]. First of all, substrates were 
divided into two categories: histologic investigations (H) and immunopathologic studies 
(I). Histologic features of heart AMR are as follows: activated mononuclear cell infiltration, 
interstitial edema, hemorrhage, necrosis, and vascular thrombosis. On the other hand, C4d, 
CD68 (paraffin section), C4d, or C3d (frozen section) are considered mandatory panels of 
immunopathologic studies. Furthermore, CD3, CD20, C3d, endothelial cell CD31 or CD34, 
complement regulatory proteins (paraffin section), and fibrin and immunoglobulin G/M (fro-
zen section) are regarded as secondary or optional panels. In total, the current report of AMR 
in heart is noted from Grade 0 to 3 as follows:
pAMR 0: negative for pathologic AMR (H0/I0)
pAMR 1(H+): histopathologic AMR (H+/I−)
pAMR 1 (I+): immunopathologic AMR (H−/I+)
pAMR 2: pathologic AMR (H+/I+)
pAMR 3: severe AMR (interstitial hemorrhage, capillary fragmentation, mixed inflammatory 
cell infiltration, endothelial cell pyknosis and/or karyorrhexis, and marked edema and I+)
pAMR 3 cases usually demonstrate severe hemodynamic dysfunction and poor consequences.
Scoring system of criteria for pathologic diagnosis of cardiac AMR is slightly different between 
immunohistochemistry and immunofluorescence analyses. These criteria are summarized in 
Table 1.
4.4. Lung transplantation
Regarding AMR following lung transplantation, the main reason is also DSA, although 
a role of non-HLA antibodies was also described [27]. Hachem et al. [28] have reported, 
in 2010, a prospective study on AMR after lung transplantation, which deepened our 
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Following heart transplantation, the onset of AMR is generally estimated around 10–20% 
[25]. In the field of heart transplantation, AMR is also considered as an important prognosis 
factor. In fact, the consequences are severe, and the development of cardiac allograft vas-
culopathy (CAV) has a huge impact. As with other organ transplantations, timing of AMR 
onset is diverse: both acute AMR within 1 week after transplantation and chronic AMR in 
the remote period can be seen. Again, allograft biopsy also plays a crucial role to accurately 
diagnose AMR. Repeated allograft biopsies seem to be required for achieving good long-term 
outcomes. Interestingly, regarding de novo DSA synthesized after 2 months following heart 
transplantation, class II DSA are dominant [25].
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(I). Histologic features of heart AMR are as follows: activated mononuclear cell infiltration, 
interstitial edema, hemorrhage, necrosis, and vascular thrombosis. On the other hand, C4d, 
CD68 (paraffin section), C4d, or C3d (frozen section) are considered mandatory panels of 
immunopathologic studies. Furthermore, CD3, CD20, C3d, endothelial cell CD31 or CD34, 
complement regulatory proteins (paraffin section), and fibrin and immunoglobulin G/M (fro-
zen section) are regarded as secondary or optional panels. In total, the current report of AMR 
in heart is noted from Grade 0 to 3 as follows:
pAMR 0: negative for pathologic AMR (H0/I0)
pAMR 1(H+): histopathologic AMR (H+/I−)
pAMR 1 (I+): immunopathologic AMR (H−/I+)
pAMR 2: pathologic AMR (H+/I+)
pAMR 3: severe AMR (interstitial hemorrhage, capillary fragmentation, mixed inflammatory 
cell infiltration, endothelial cell pyknosis and/or karyorrhexis, and marked edema and I+)
pAMR 3 cases usually demonstrate severe hemodynamic dysfunction and poor consequences.
Scoring system of criteria for pathologic diagnosis of cardiac AMR is slightly different between 
immunohistochemistry and immunofluorescence analyses. These criteria are summarized in 
Table 1.
4.4. Lung transplantation
Regarding AMR following lung transplantation, the main reason is also DSA, although 
a role of non-HLA antibodies was also described [27]. Hachem et al. [28] have reported, 
in 2010, a prospective study on AMR after lung transplantation, which deepened our 
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understanding of clinical AMR managements. In 2016, a consensus statement has been 
proposed from the international society for heart and lung transplantation [29].
Lung allograft AMR can be divided into clinical and subclinical AMR, depending on whether 
there is allograft dysfunction or not. Next, as similar to other organs, these clinical and sub-
clinical AMR are subcategorized as define, probable, or possible. To determine certainty of 
clinical AMR, the following five criteria are proposed: allograft dysfunction, other causes 
excluded, lung histology, lung biopsy C4d, and s-DSA. Define lung AMR is determined by 
positive for all five criteria. In case anyone of them is negative, it is considered as probable 
AMR, excluding allograft dysfunction (Table 2). There are histopathologic features of AMR, 
including the following—neutrophil margination, neutrophil capillaritis/arteritis without any 
signs of pneumonia, or other apparent reasons—though these features are not specific for lung 
AMR. In terms of lung histology, further advancement and organization would be required.
4.5. Small bowel transplantation
Due to recent increased recognition of AMR, AMR is also considered as a serious issue in the 
small bowel transplantation field. However, the define diagnosis criteria have not been estab-
lished in the small bowel transplantation yet. There are few series of case reports in terms of 
intestine AMR. Although common understandings of AMR also seem to be C4d deposition, 
capillaritis, and s-DSA positivity [30], there is a report which did not find clinical evidence 
between C4d positivity and the onset of AMR [31]. The establishment of diagnostic criteria 
should be required to standardize and manage AMR in intestine transplantation. The future 
contribution of g-DSA assessment would be also expected in this field.
Immunohistochemistry scoring system Immunofluorescence scoring system
Capillary C4d 
distribution
0 < 10% Negative Capillary C4d/
C3d distribution
0 < 10% Negative
1 10–50% Focal 1 10–50% Focal
2 > 50% multifocal/
diffuse
2 > 50% Multifocal/diffuse
Capillary C4d 
intensity
0 Negative/equivocal Capillary C4d/
C3d intensity
0 Negative/equivocal
1 Faint positive 1 Faint positive = 0–1+




0 < 10% Negative HLA-DR 
distribution
0 < 10% Negative
1 10–50% Focal 1 10–50% Focal
2 > 50% Multifocal/
diffuse
2 > 50% Multifocal/diffuse
HLA-DR intensity 0 Negative/equivocal
1 Faint positive = 0–1+
2 Strong positive = 2–3+
Table 1. Immunohistochemistry and immunofluorescence scoring system in heart AMR.
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5. Preoperative desensitization
To perform organ transplantation between a sensitized recipient and donor pair, preoperative 
desensitization is required. Generally, crossmatch positive organ transplantation is mainly 
performed in kidney and liver transplantation. Desensitization can be divided into three main 
treatments: depletion/modification of B cells, apheresis for antibodies, and inhibition of reac-
tion between DSA and HLA. The golden standard of B-cell depletion therapy is rituximab 
(anti-CD20 antibodies) administration [32–35]. There are a wide variety of rituximab admin-
istration protocols in terms of a dosage and schedule. In our institution, generally, rituximab 
(375 mg/m2) is administered in 2 weeks prior to organ transplantation [20]. Subsequent B-cell 
count in the peripheral blood is measured by flow cytometry. In addition to rituximab, to 
deplete B cells, anti-CD52 antibodies (alemtuzumab) also can be used, because higher than 
95% B cells express CD52 on the cell surface [36]. It has been reported that alemtuzumab-
combined regimens are safe and effective for highly sensitized recipients [36, 37]. Other anti-
bodies’ introduction would be expected regarding induction regimens.
To decrease DSA production and reaction, the importance of intravenous immune globulin 
(IVIG) has been reported. IVIG infusion significantly decreased the baseline flowPRA levels 
[38]. There is a variety of reports regarding the dosage and duration of IVIG (100 mg/kg/
day–4 g/kg/day, etc.), partially due to the cost problems.
Regarding apheresis therapy, double filtration plasmapheresis (DFPP) or plasma exchange 
(PE) is generally performed. Usually, as an index of DSA titer, MFI has gained its popularity. 
Given the fact of g-DSA and s-DSA assessments, DSA with MFI < 2500 might not deposit and 
cause clinical damages to allografts. Thus, although it depends on each institution, accept-
able DSA MFI prior to surgery might be estimated around 2000 [20] in renal transplanta-
tion. However, on the other hand, intensive posttransplant desensitization also can result in 
Allograft dysfunction Other causes 
excluded
Lung histology compatible with 
AMR
C4d s-DSA
Define + + + + +
Probable* + + + − +
+ − + + +
+ + − + +
+ + + + −
Possible + − − + +
+ + − − +
+ + + − −
+ − + − +
+ − + + −
+ + − + −
There is growing evidence that C4d negative AMR exists. Thus, the second line * cases are considered as an independent 
group.
Table 2. Lung AMR diagnosis criteria.
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comparable outcomes with non-sensitized transplantation [39]. For highly sensitized recipi-
ents, a phased desensitization protocol by using rituximab and bortezomib was advocated 
[34]. In fact, it is true that rituximab administration can deplete B cells but not plasma cells. 
Thus, it is reasonable to believe that rituximab and bortezomib combination therapy eradi-
cates the B-cell linage which is potentially associated with AMR.
Furthermore, the idea only relying on MFI might be unrefined. In other words, the quality of 
DSA is also important to determine the impact of DSA. Regarding the quality, IgG subclasses 
[1–4, 40] and complement fixing ability [41] seem to be paid attention, considering the severity 
of subsequent AMR and graft survival.
On the other hand, in liver transplantation, there seems to be no concrete evidence regarding 
DSA MFI just prior to transplantation. A large amount of hemorrhage during surgery and liver 
allograft resistance against DSA, etc., might complicate to set a MFI threshold. Nevertheless, 
Yoshizawa et al. [42] reported that class I DSA MFI > 10,000 has a negative impact on graft 
survival. Thus, it is important to keep circumstances where allograft injury due to remnant 
DSA is minimum and additional DSA production inhibited.
6. Treatment for antibody-mediated rejection
In other words, this is a treatment for B cells/plasma cells and DSA and reaction between DSA 
and HLA. Both for acute AMR and chronic active AMR, generally clinical managements also 
can be divided into medications and apheresis: steroid pulse, IVIG, Rituximab, etc., and DFPP 
or PE. In severe cases, it is true that splenectomy has a certain effect on AMR [43]. Regarding 
treatment for acute AMR, the concepts are the same: depletion of B cells, reduction of DSA, 
and inhibition of reaction between DSA and HLA. The core agents and methods are sum-
marized in Table. It is true that high-dose steroid administration is effective on all aspects of 
AMR treatment. There is no fixed data to determine the dosage and duration of steroid pulse 
therapy. However, generally, 10–100 mg/kg/day equivalent dosage of hydrocorticoid is admin-
istered as steroid pulse therapy, depending on the severity of AMR. For depletion of B cells, 
rituximab, alemtuzumab, or splenectomy is utilized. To reduce DSA, DFPP, or PE, apheresis 
methods are commonly used in the same way as desensitization. As immunomodulation, IVIG 
administration also plays an important role in controlling acute AMR. Given the fact of AMR 
pathogenesis, complement activation should be paid attention. Final tissue injury due to AMR 
would occur following activation of antibody-induced terminal complement cascade. Albeit 
limited evidence, it has been reported that eculizumab C5 inhibitor is effective to rescue an 
AMR allograft [44–47].
Recently, chronic active AMR has been paid strong attention, because this pathologic con-
dition directly deteriorates the long-term graft survival. Despite the recognition of chronic 
active AMR, diagnostic criteria are only established in kidney [21] and liver transplantation 
[22]. There seems to be no therapeutic consensus on this condition. Furthermore, it has gen-
erally resistance to ordinal AMR managements discussed above [48–50], although limited 
effectiveness was observed in few studies [51, 52]. Bachelet et al. [50] reported a treatment for 
chronic active AMR (mean eGFR 30.6 mL/min/1.73 m2) by utilizing rituximab (375 mg/m2) and 
IVIG (1 g/kg/week × 4 weeks). Although serum MFI tends to decrease, there is no difference in 
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2-year graft survival between the treatment (47%) and without treatment groups (40%). These 
reports suggest a difficulty in the management for chronic changes in allografts. In addition 
to acute AMR, eculizumab was also challenged for chronic active AMR. Although there were 
no notable differences in eGFR between treatment and control groups, C1q-positive recipients 
demonstrated significant better eGFR than recipients with C1q-negative status [53]. Inhibition 
of complement-dependent allograft injury would bring benefits on certain population. Recent 
reports discussing treatment for chronic active AMR are summarized in Table 3.
In total, it is of vital importance to prevent from developing into chronic lesions and initiate 
appropriate treatment in the early stages of AMR, because fully established chronic lesions 
are irreversible. It is reasonable to believe that these managements lead to improvements of 
the long-term allograft survival.
7. Conclusion
Under the present circumstances, it is of vital importance to control AMR in advance in order 
to improve graft survival rate in all fields of organ transplantation. To detect early-stage AMR, 
clinicians need to be aware of recent advances in DSA analyses, including graft ICFA and an 
acid elution method to assess intra-graft DSA status. Preoperative desensitization therapies 
and management plans are decided depending on classes of DSA and s-DSA MFI. Conversely, 
Treatment for chronic active AMR
Author Organ Treatment Schedule Outcomes
Billing 2012 
[51]
Kidney IVIG; Rit 1 g/kg/week for 4 weeks; 
375 mg/m2 × 1
The treatment reduced or stabilized 
the progressive loss of transplant 
function in pediatric patients
Cooper 2014 
[49]
Kidney IVIG High-dose (5 g/kg) IVIG dosed 
over 6 months
No clinical treatment benefit
An 2014* 
[54]




Kidney IVIG; Rit 1 g/kg/week for 4 weeks; 
375 mg/m2/week in the first 2 
weeks
The treatment did not seem to 
change the natural history of AMR
Redfield 
2016 [55]
Kidney Dex; IVIG; Rit (PE, 
Thymoglobulin)
100 mg of Dex; 4 weekly doses 





Kidney Eculizmab 600 mg/week for 4 weeks 
followed by 900 mg every 2 
weeks for a total of 26 weeks




Kidney Dex; IVIG; Rit 100 mg; 200 mg/kg/2 weeks for 
3 weeks; 375 mg/m2/week
The treatment was effective in 




Kidney IVIG; Rit 400 mg/kg × 4 days; 375 mg/m2 The treatment reduced the 
progression of CAMR
*: Reported from the same group.
Table 3. Summary of recent reports on treatments for chronic active antibody-mediated rejection (AMR).
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or PE. In severe cases, it is true that splenectomy has a certain effect on AMR [43]. Regarding 
treatment for acute AMR, the concepts are the same: depletion of B cells, reduction of DSA, 
and inhibition of reaction between DSA and HLA. The core agents and methods are sum-
marized in Table. It is true that high-dose steroid administration is effective on all aspects of 
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methods are commonly used in the same way as desensitization. As immunomodulation, IVIG 
administration also plays an important role in controlling acute AMR. Given the fact of AMR 
pathogenesis, complement activation should be paid attention. Final tissue injury due to AMR 
would occur following activation of antibody-induced terminal complement cascade. Albeit 
limited evidence, it has been reported that eculizumab C5 inhibitor is effective to rescue an 
AMR allograft [44–47].
Recently, chronic active AMR has been paid strong attention, because this pathologic con-
dition directly deteriorates the long-term graft survival. Despite the recognition of chronic 
active AMR, diagnostic criteria are only established in kidney [21] and liver transplantation 
[22]. There seems to be no therapeutic consensus on this condition. Furthermore, it has gen-
erally resistance to ordinal AMR managements discussed above [48–50], although limited 
effectiveness was observed in few studies [51, 52]. Bachelet et al. [50] reported a treatment for 
chronic active AMR (mean eGFR 30.6 mL/min/1.73 m2) by utilizing rituximab (375 mg/m2) and 
IVIG (1 g/kg/week × 4 weeks). Although serum MFI tends to decrease, there is no difference in 
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reports discussing treatment for chronic active AMR are summarized in Table 3.
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even in crossmatch-negative cases, there is a possibility that memory B cells might evoke 
severe AMR 1 week following transplantation. In addition, there might be a discrepancy 
between s-DSA and g-DSA. It is also true that only relying on s-DSA MFI is difficult to deter-






ICFA immunocomplex capture fluorescence analysis
LCT lymphocyte cytotoxic test
FCXM flow cytometry crossmatch
SAB single antigen bead assay
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Abstract
In 2016, the global health sector strategy (GHSS) on viral hepatitis called for elimination 
of hepatitis B as a major public health threat by 2030 (i.e., 90% reduction in incidence and 
65% in mortality). But persistence or clearance of hepatitis B virus (HBV) infection mainly 
depends upon host immune responses. The human leukocyte antigen (HLA) system is 
the center of host immune responses. HLA genes are located in chromosome 6p21.31 
and cover 0.13% of the human genome and show a high degree of polymorphism and 
extensive patterns of linkage disequilibrium (LD), which differ among populations. The 
HLA genes include HLA class I, HLA class II, and other non-HLA alleles. HLA class 
II gene polymorphisms are strongly associated with not only persistent HBV infection 
but also spontaneous HBV clearance and seroconversion, disease progression, and the 
development of liver cirrhosis (LC) and HBV-related hepatocellular carcinoma (HCC) in 
chronic hepatitis B. This chapter summarizes the reported associations of HLA class II 
gene polymorphisms with the outcomes of HBV infection and their related mechanisms.
Keywords: HBV, HBV infection, HLA, HLA class II gene polymorphisms
1. Introduction
Since the discovery of hepatitis B virus (HBV) by Blumberg et al. in 1965, much has been elu-
cidated regarding its virion, infection, prevention, and treatment [1, 2]. However, HBV infec-
tion continues to be a significant public health problem that has not yet been fully addressed 
worldwide [3, 4].
HBV infection is caused by HBV, an enveloped DNA virus that infects the liver causing 
hepatocellular inflammation and necrosis. HBV infection can be either acute or chronic, and 
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the associated illness ranges in severity from asymptomatic to symptomatic and progressive 
disease. Chronic hepatitis B (CHB) is defined as persistence of hepatitis B surface antigen 
(HBsAg) for 6 months or more [2]. The World Health Organization (WHO) reports that 
80–90% of infants infected during the first year of life and 30–50% of children infected before 
the age of 6 years develop chronic infections; less than 5% of otherwise healthy persons who 
are infected as adults will develop chronic infection; and 20–30% of adults who are chroni-
cally infected will develop cirrhosis and/or liver cancer [4]. In 2015, 257 million people lived 
with HBV infection defined as hepatitis B surface antigen positive; and hepatitis B resulted in 
887,000 deaths, mostly from complications including liver cirrhosis (LC) and hepatocellular 
carcinoma (HCC) [4]. Once infected with HBV, one of the main risks is the development of 
cirrhosis, hepatic decompensation, and ultimately HCC [2–6]. In 2016, the global health sector 
strategy (GHSS) on viral hepatitis called for elimination of viral hepatitis as a major public 
health threat by 2030 (i.e., 90% reduction in incidence and 65% in mortality) [5]. In 2017, 
WHO’s first-ever Global hepatitis report presented the baseline values for each of the core 
indicators of the strategy [6].
The prevention component of elimination is on track with respect to hepatitis B vaccination, 
blood safety, and injection safety [7–10]. A promising but limited start in hepatitis testing 
and treatment needs to be followed by immediate and sustained action so that we reach the 
service coverage targets required to achieve elimination by 2030 [3]. Levrero et al. [11], Vyas 
et al. [12], and Yoo et al. [13] reviewed that multiple emerging drug therapies are currently in 
the early stages of development as part of the growing effort to find a true cure for HBV. But 
persistence or clearance of HBV infection mainly depends upon host immune responses.
The major histocompatibility complex (MHC) was discovered in the mouse in 1936 [14]. 
The human leukocyte antigen (HLA) system, MHC in humans, is the center of host immune 
responses [15–17]. HLA genes are located in chromosome 6p21.31 [18] and cover 0.13% of the 
human genome [19] and show a high degree of polymorphism and extensive patterns of link-
age disequilibrium (LD), which differ among populations. The HLA genes include HLA class I, 
HLA class II, and other non-HLA alleles [20]. HLA class I alleles include the three classic HLA 
gene loci: HLA-A, HLA-B, and HLA-C; three non-classic HLA-E, HLA-F, and HLA-G gene 
loci, which show limited polymorphism compared to the classic class I loci; and other related 
non-coding genes and pseudogenes [20]. The main function of HLA class I molecules, which 
are expressed in all nucleated cells, is to present non-self antigens derived from intracellular 
sources, such as viruses, to CD8+ T cells (cytotoxic T cells, CTL), which then identify and kill 
infected cells [21]. CD8+ T cells interact with the cognate peptide-MHC I complexes via their 
T-cell receptor (TCR) and co-receptor molecule CD8. HLA class II alleles include the classic 
gene loci HLA-DR, HLA-DQ, and HLA-DP and also the non-classic HLA-DO and HLA-DM 
loci [20]. The classic genes are expressed on the surface of professional antigen-presenting 
cells (APCs), which take up antigens derived from extracellular sources [22], such as bacteria 
or food, and present them to CD4+ T helper cells. This leads to the secretion of various small 
proteins, including cytokines, which regulate other immune cells such as macrophages or B 
cells. In turn, macrophages can destroy ingested microbes, and activated B cells can secrete 
antibodies. CD4+ T cells interact with the cognate peptide-MHC II complexes via their TCR 
and the co-receptor molecule CD4. Non-classic molecules are exposed in internal membranes 
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in lysosomes, which help load antigenic peptides on to classic MHC class II molecules. Over 
the past 50 years, polymorphisms in the HLA locus have been shown to influence many criti-
cal biological traits and individuals’ susceptibility to complex, autoimmune, and infectious 
diseases [17, 23, 24]. Since 1979, Kew et al. [25] started the research for the association between 
histocompatibility antigens and HBV infection, and a plenty of researches demonstrated that 
the highly polymorphic HLA classes I and II genes can affect the ability of HLA molecules 
to trigger immune responses, which affects the outcomes of HBV infection, and discrepant 
conclusions were reached in different cohorts [26, 27]. HLA class II gene polymorphisms are 
strongly associated with not only persistent HBV infection but also spontaneous HBV clear-
ance and seroconversion, disease progression, and the development of LC and HBV-related 
HCC in chronic hepatitis B [28–30]. This chapter summarizes the reported associations of 
HLA class II gene polymorphisms with susceptibility to HBV infection, resolution, and dis-
ease progression and their related mechanisms.
2. HLA class II gene and the clinical outcomes of HBV infection
HLA class II gene includes HLA-DRA1, -DRB1~9, -DQA1, -DQB1, -DPA1, -DPA2, -DPB1, -DPB2, 
-DOA, -DOB, -DMA, and -DMB with 4857 alleles known with the latest report update on 
April 16, 2018 (http://www.ebi.ac.uk/imgt/hla/stats.html). HLA-DRB1 has the most allelic 
variability with 2165 alleles, and in turn HLA-DQB1 with 1196 alleles, HLA-DPB1 with 975 
alleles, and HLA-DRB3 with 157 alleles [20].
2.1. HLA class II allele polymorphism and HBV infection outcomes
HLA-DR is widely used in transplant gene matching [31] and as an activated T cell surface 
marker [32], and early related to the clinical outcomes of HBV infection [33]. In 2013, we 
reviewed the relationship between HLA class II alleles and HBV infection, there are the most 
number of HLA-DR alleles relatived to HBV infection, such as HLA-DRB1*03, 07, 09 and 12, 
may be the risk factors of HBV infection; and HLA-DRB1*04, 11, 13 and 14 may be the protect 
factors of HBV infection [26]. In 2016, Wang et al. also reviewed the relationship of HLA-DR 
alleles with HBV infection [27], including HLA-DRB1*1301-02 which is consistently associated 
with HBV clearance globally, such as in Gambia, Germany, Korea, and Spain; HLA-DRB1*11 
and -DRB1*14 are associated with spontaneous recovery in patients with HBV subgenotype 
C2 infection in Northeast China; HLA-DR2, HLA-DR*0406, and HLA-DR7 antigens are associ-
ated with protective effect on acute HBV infection; and HLA-DRB1*08 and -DRB1*09 alleles, 
which are susceptible to HBV infection, were found in Brazilian populations determined in 
young and male blood donors. Meanwhile, HLA-DRB1*11/12 alleles are associated with HBV 
persistence globally, and HLA-DRB1*07 is the only one associated with infant susceptibility 
to intrauterine HBV infection and a significant negative predictor of cirrhosis. Our researches 
also showed that: -DRB1*13 may protect subjects from HBV infection [26]; -DRB1*12 may have 
a high risk for HBV infection [26]; and -DRB1*07 and 12 may be implied in viral persistence 
[26, 34]. Analysis still identified HLA-DRB1*12:02 as the top susceptible HLA allele associ-
ated with acute-on-chronic liver failure (ACLF) [35]. A large number of studies have been 
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carcinoma (HCC) [4]. Once infected with HBV, one of the main risks is the development of 
cirrhosis, hepatic decompensation, and ultimately HCC [2–6]. In 2016, the global health sector 
strategy (GHSS) on viral hepatitis called for elimination of viral hepatitis as a major public 
health threat by 2030 (i.e., 90% reduction in incidence and 65% in mortality) [5]. In 2017, 
WHO’s first-ever Global hepatitis report presented the baseline values for each of the core 
indicators of the strategy [6].
The prevention component of elimination is on track with respect to hepatitis B vaccination, 
blood safety, and injection safety [7–10]. A promising but limited start in hepatitis testing 
and treatment needs to be followed by immediate and sustained action so that we reach the 
service coverage targets required to achieve elimination by 2030 [3]. Levrero et al. [11], Vyas 
et al. [12], and Yoo et al. [13] reviewed that multiple emerging drug therapies are currently in 
the early stages of development as part of the growing effort to find a true cure for HBV. But 
persistence or clearance of HBV infection mainly depends upon host immune responses.
The major histocompatibility complex (MHC) was discovered in the mouse in 1936 [14]. 
The human leukocyte antigen (HLA) system, MHC in humans, is the center of host immune 
responses [15–17]. HLA genes are located in chromosome 6p21.31 [18] and cover 0.13% of the 
human genome [19] and show a high degree of polymorphism and extensive patterns of link-
age disequilibrium (LD), which differ among populations. The HLA genes include HLA class I, 
HLA class II, and other non-HLA alleles [20]. HLA class I alleles include the three classic HLA 
gene loci: HLA-A, HLA-B, and HLA-C; three non-classic HLA-E, HLA-F, and HLA-G gene 
loci, which show limited polymorphism compared to the classic class I loci; and other related 
non-coding genes and pseudogenes [20]. The main function of HLA class I molecules, which 
are expressed in all nucleated cells, is to present non-self antigens derived from intracellular 
sources, such as viruses, to CD8+ T cells (cytotoxic T cells, CTL), which then identify and kill 
infected cells [21]. CD8+ T cells interact with the cognate peptide-MHC I complexes via their 
T-cell receptor (TCR) and co-receptor molecule CD8. HLA class II alleles include the classic 
gene loci HLA-DR, HLA-DQ, and HLA-DP and also the non-classic HLA-DO and HLA-DM 
loci [20]. The classic genes are expressed on the surface of professional antigen-presenting 
cells (APCs), which take up antigens derived from extracellular sources [22], such as bacteria 
or food, and present them to CD4+ T helper cells. This leads to the secretion of various small 
proteins, including cytokines, which regulate other immune cells such as macrophages or B 
cells. In turn, macrophages can destroy ingested microbes, and activated B cells can secrete 
antibodies. CD4+ T cells interact with the cognate peptide-MHC II complexes via their TCR 
and the co-receptor molecule CD4. Non-classic molecules are exposed in internal membranes 
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in lysosomes, which help load antigenic peptides on to classic MHC class II molecules. Over 
the past 50 years, polymorphisms in the HLA locus have been shown to influence many criti-
cal biological traits and individuals’ susceptibility to complex, autoimmune, and infectious 
diseases [17, 23, 24]. Since 1979, Kew et al. [25] started the research for the association between 
histocompatibility antigens and HBV infection, and a plenty of researches demonstrated that 
the highly polymorphic HLA classes I and II genes can affect the ability of HLA molecules 
to trigger immune responses, which affects the outcomes of HBV infection, and discrepant 
conclusions were reached in different cohorts [26, 27]. HLA class II gene polymorphisms are 
strongly associated with not only persistent HBV infection but also spontaneous HBV clear-
ance and seroconversion, disease progression, and the development of LC and HBV-related 
HCC in chronic hepatitis B [28–30]. This chapter summarizes the reported associations of 
HLA class II gene polymorphisms with susceptibility to HBV infection, resolution, and dis-
ease progression and their related mechanisms.
2. HLA class II gene and the clinical outcomes of HBV infection
HLA class II gene includes HLA-DRA1, -DRB1~9, -DQA1, -DQB1, -DPA1, -DPA2, -DPB1, -DPB2, 
-DOA, -DOB, -DMA, and -DMB with 4857 alleles known with the latest report update on 
April 16, 2018 (http://www.ebi.ac.uk/imgt/hla/stats.html). HLA-DRB1 has the most allelic 
variability with 2165 alleles, and in turn HLA-DQB1 with 1196 alleles, HLA-DPB1 with 975 
alleles, and HLA-DRB3 with 157 alleles [20].
2.1. HLA class II allele polymorphism and HBV infection outcomes
HLA-DR is widely used in transplant gene matching [31] and as an activated T cell surface 
marker [32], and early related to the clinical outcomes of HBV infection [33]. In 2013, we 
reviewed the relationship between HLA class II alleles and HBV infection, there are the most 
number of HLA-DR alleles relatived to HBV infection, such as HLA-DRB1*03, 07, 09 and 12, 
may be the risk factors of HBV infection; and HLA-DRB1*04, 11, 13 and 14 may be the protect 
factors of HBV infection [26]. In 2016, Wang et al. also reviewed the relationship of HLA-DR 
alleles with HBV infection [27], including HLA-DRB1*1301-02 which is consistently associated 
with HBV clearance globally, such as in Gambia, Germany, Korea, and Spain; HLA-DRB1*11 
and -DRB1*14 are associated with spontaneous recovery in patients with HBV subgenotype 
C2 infection in Northeast China; HLA-DR2, HLA-DR*0406, and HLA-DR7 antigens are associ-
ated with protective effect on acute HBV infection; and HLA-DRB1*08 and -DRB1*09 alleles, 
which are susceptible to HBV infection, were found in Brazilian populations determined in 
young and male blood donors. Meanwhile, HLA-DRB1*11/12 alleles are associated with HBV 
persistence globally, and HLA-DRB1*07 is the only one associated with infant susceptibility 
to intrauterine HBV infection and a significant negative predictor of cirrhosis. Our researches 
also showed that: -DRB1*13 may protect subjects from HBV infection [26]; -DRB1*12 may have 
a high risk for HBV infection [26]; and -DRB1*07 and 12 may be implied in viral persistence 
[26, 34]. Analysis still identified HLA-DRB1*12:02 as the top susceptible HLA allele associ-
ated with acute-on-chronic liver failure (ACLF) [35]. A large number of studies have been 
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conducted to identify HLA-DRB1 genetic variants associated with HCC risk and clinical out-
comes, but many of the findings in these studies are inconsistent and inconclusive [36–38]. 
A meta-analysis by Lin et al. reported an ethnicity-dependent association between specific 
HLA-DRB1 alleles and HCC risk, DRB1*07 and DRB1*12 were significantly associated with 
the risk of HCC in the whole populations, and DRB1*15 allele significantly increased the 
risk of hepatocellular carcinoma only in Asians [36]. One research by Ma et al. suggests that 
if genetic factors play a role in familial aggregation of hepatocellular carcinoma, the defi-
ciency in the DRB1*11 and DRB1*12 alleles might be the risk factor at work in the Guangxi 
Zhuang Autonomous Region, P.R.C. [37]. Another meta-analysis by Liu et al. reported that 
HLA-DRB1*01 and 11 alleles were protective factors, while HLA-DRB1*12 and 14 alleles were 
risk factors for HCC development [38]. These findings are somewhat reasonable considering 
the incidence and distribution of HCC which are closely linked to environmental, dietary, 
and lifestyle factors, as well as genetic profiles, but the risk for HCC was not controlled for 
possible confounders such as HBV or HCV, which are more prone to bias than that of the 
randomized clinical trial studies.
HLA-DQ belongs to one of HLA class II molecules; it is also expressed as cell-surface glycopro-
teins that bind to exogenous antigens and present them to CD4+ T cells. HLA-DQ molecules 
function as a heterodimer of alpha and beta subunits which are encoded by the HLA-DQA1 
and HLA-DQB1 genes, respectively. HLA-DQs are highly polymorphic especially in exon 2 
which encode antigen-binding sites. Therefore, a number of alleles have been declared to 
be associated with persistent HBV infection [26, 27]—HLA-DQA1*0102, 0201, 0301, and 0402 
and HLA-DQB1*0604, and so on associated with HBV clearance; and HLA-DQA1*0103, 0201, 
0302, and 0501 and HLA DQB1*0301, and so on associated with HBV persistence [26]; the two-
locus haplotype consisting of -DQA1*0501 and -DQB1*0301, and the three-locus haplotype 
consisting of -DQA1*0501, -DQB1*0301, and -DRB1*1102 were significantly associated with 
persistent HBV infection in an African-American cohort; -DQB1*0301 was associated with 
HBV persistence globally; in addition, -DQB1*0201 is a HBV-resistant gene, and -DQB1*0303 
is a susceptibility gene of carrying HBV in Xinjiang Uygur ethnic groups of China; and 
-DQB1*0503 are associated with early HBeAg seroconversion in CHB children in Taiwan [27]. 
HLA genotyping-based analysis identified -DQB1*0601 as having the strongest association, 
showing a greater association with CHB susceptibility [28].
The HLA DPA1 and HLA DPB1 belong to the HLA class II alpha and beta chain paralogs, 
which also make a heterodimer consisting of an alpha and a beta chain on the surface of 
antigen-presenting cells. This HLA class II molecule also plays a central role in the immune 
system by presenting peptides derived from extracellular proteins. Identification of a total 
of five alleles, including two risk alleles (DPB1*09:01 and DPB1*05:01) and three protective 
alleles (DPB1*04:01, DPB1*04:02, and DPB1*02:01), would enable HBV-infected individuals 
to be classified into groups according to the treatment requirements. Moreover, among the 
five reported HLA-DPB1 susceptibility alleles, three DPB1 alleles (DPB1*05:01, *02:01, and 
*04:02) had primary effects on CHB susceptibility. However, the association of the remaining 
two alleles (DPB1*09:01 and *04:01) had come from LD with HLA-DR-DQ haplotypes (i.e., 
DRB1*15:02-DQB1*06:01 and DRB1*13:02-DQB1*06:04, respectively) [28, 39].
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2.2. Single nucleotide polymorphisms at HLA class II gene and HBV infection 
outcomes
HLA gene variations are strongly associated with HBV infection outcomes in not only HLA 
alleles but also single nucleotide polymorphisms (SNPs) identified through genome-wide 
associated studies (GWASs). Recent GWASs have revealed several SNPs at HLA class II 
region associated with the risk of HBV infection [23, 30].
A Chinese study by Zhu et al. [40] identified two HLA-DR loci that independently drive 
chronic HBV infection, including HLA-DRβ113 sites 71 and rs400488. Acute-on-chronic liver 
failure (ACLF) is an extreme condition after severe acute exacerbation of chronic hepatitis 
B. Tan et al. carried out a genome-wide association study, among 1300 ACLFs and 2087 AsCs, 
and identified rs3129859 at HLA class II region (chromosome 6p21.32) which is associated 
with HBV-related ACLF. Analysis identified HLA-DRB1*12:02 as the top susceptible HLA 
allele associated with ACLF. The association of rs3129859 was robust in ACLF subgroups 
or HBV e antigen-negative chronic hepatitis B phase. Clinical traits analysis in patients with 
ACLF showed that the risky rs3129859*C allele was also associated with prolonged pro-
thrombin time, faster progression to ascites development, and higher 28-day mortality [35]. 
SNP rs9272105 locates between HLA-DQA1 and HLA-DRB1 on 6p21.32. SNP imputation in 
the GWAS discovery samples revealed additional SNPs showing association, but rs9272105 
remained the top SNP within the region [41], which successfully validated the associations 
between rs9272105 and HCC risk [42]. Of the 12 SNPs reported in HBV-related HCC GWASs, 
rs2647073 and rs3997872 near HLA-DRB1 were found to be significantly associated with the 
risk of HBV-related LC, which suggested that genetic variants associated with HBV-related 
hepatocarcinogenesis may already play an important role in the progression from CHB to 
LC [43]. A recent study reported new SNPs at HLA-DRB1 (rs35445101) associated with TP53 
expression status in HBV-related hepatocellular carcinoma [30].
In 2013, Jiang et al. first found the association of HCC risk with rs9275319 at 6p21.3 located 
between HLA-DQB1 and HLA-DQA2, which was not reported in earlier GWASs of HCC [44]. 
Their following research and that of Wen et al. successfully validated the associations between 
rs9275319 and HCC risk [42, 43]. Three SNPs belonging to the HLA-DQ region (rs2856718, 
rs7453920, and rs9275572) were studied. HLA-DQ rs2856718G, rs7453920A, and rs9275572A 
were strongly associated with decreased risk of chronic HBV infection and natural clearance; 
while rs2856718A, rs7453920G, and rs9275572G served as a risk factor in HBV infection in 
Japanese populations and in Southeast China [45–48]. Chang et al. found that rs9276370 
(HLA-DQA2), rs7756516, and rs7453920 (HLA-DQB2) are significantly associated with persis-
tent HBV infection, especially the “T-T” haplotype composed of rs7756516 and rs9276370 that 
is more prevalent in severe disease subgroups and associated with nonsustained therapeutic 
response in male Taiwan Han Chinese individuals [49]. A nearest study reported four new 
SNPs at HLA-DQB1 (rs1130399, rs1049056, rs1049059, and rs1049060) associated with TP53 
expression status in HBV-related HCC [30].
A Chinese study by Zhu et al. [40] identified HLA-DPβ1 positions 84–87 that indepen-
dently drive chronic HBV infection. In 2009, Kamatani et al. first reported two SNPs with 
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conducted to identify HLA-DRB1 genetic variants associated with HCC risk and clinical out-
comes, but many of the findings in these studies are inconsistent and inconclusive [36–38]. 
A meta-analysis by Lin et al. reported an ethnicity-dependent association between specific 
HLA-DRB1 alleles and HCC risk, DRB1*07 and DRB1*12 were significantly associated with 
the risk of HCC in the whole populations, and DRB1*15 allele significantly increased the 
risk of hepatocellular carcinoma only in Asians [36]. One research by Ma et al. suggests that 
if genetic factors play a role in familial aggregation of hepatocellular carcinoma, the defi-
ciency in the DRB1*11 and DRB1*12 alleles might be the risk factor at work in the Guangxi 
Zhuang Autonomous Region, P.R.C. [37]. Another meta-analysis by Liu et al. reported that 
HLA-DRB1*01 and 11 alleles were protective factors, while HLA-DRB1*12 and 14 alleles were 
risk factors for HCC development [38]. These findings are somewhat reasonable considering 
the incidence and distribution of HCC which are closely linked to environmental, dietary, 
and lifestyle factors, as well as genetic profiles, but the risk for HCC was not controlled for 
possible confounders such as HBV or HCV, which are more prone to bias than that of the 
randomized clinical trial studies.
HLA-DQ belongs to one of HLA class II molecules; it is also expressed as cell-surface glycopro-
teins that bind to exogenous antigens and present them to CD4+ T cells. HLA-DQ molecules 
function as a heterodimer of alpha and beta subunits which are encoded by the HLA-DQA1 
and HLA-DQB1 genes, respectively. HLA-DQs are highly polymorphic especially in exon 2 
which encode antigen-binding sites. Therefore, a number of alleles have been declared to 
be associated with persistent HBV infection [26, 27]—HLA-DQA1*0102, 0201, 0301, and 0402 
and HLA-DQB1*0604, and so on associated with HBV clearance; and HLA-DQA1*0103, 0201, 
0302, and 0501 and HLA DQB1*0301, and so on associated with HBV persistence [26]; the two-
locus haplotype consisting of -DQA1*0501 and -DQB1*0301, and the three-locus haplotype 
consisting of -DQA1*0501, -DQB1*0301, and -DRB1*1102 were significantly associated with 
persistent HBV infection in an African-American cohort; -DQB1*0301 was associated with 
HBV persistence globally; in addition, -DQB1*0201 is a HBV-resistant gene, and -DQB1*0303 
is a susceptibility gene of carrying HBV in Xinjiang Uygur ethnic groups of China; and 
-DQB1*0503 are associated with early HBeAg seroconversion in CHB children in Taiwan [27]. 
HLA genotyping-based analysis identified -DQB1*0601 as having the strongest association, 
showing a greater association with CHB susceptibility [28].
The HLA DPA1 and HLA DPB1 belong to the HLA class II alpha and beta chain paralogs, 
which also make a heterodimer consisting of an alpha and a beta chain on the surface of 
antigen-presenting cells. This HLA class II molecule also plays a central role in the immune 
system by presenting peptides derived from extracellular proteins. Identification of a total 
of five alleles, including two risk alleles (DPB1*09:01 and DPB1*05:01) and three protective 
alleles (DPB1*04:01, DPB1*04:02, and DPB1*02:01), would enable HBV-infected individuals 
to be classified into groups according to the treatment requirements. Moreover, among the 
five reported HLA-DPB1 susceptibility alleles, three DPB1 alleles (DPB1*05:01, *02:01, and 
*04:02) had primary effects on CHB susceptibility. However, the association of the remaining 
two alleles (DPB1*09:01 and *04:01) had come from LD with HLA-DR-DQ haplotypes (i.e., 
DRB1*15:02-DQB1*06:01 and DRB1*13:02-DQB1*06:04, respectively) [28, 39].
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2.2. Single nucleotide polymorphisms at HLA class II gene and HBV infection 
outcomes
HLA gene variations are strongly associated with HBV infection outcomes in not only HLA 
alleles but also single nucleotide polymorphisms (SNPs) identified through genome-wide 
associated studies (GWASs). Recent GWASs have revealed several SNPs at HLA class II 
region associated with the risk of HBV infection [23, 30].
A Chinese study by Zhu et al. [40] identified two HLA-DR loci that independently drive 
chronic HBV infection, including HLA-DRβ113 sites 71 and rs400488. Acute-on-chronic liver 
failure (ACLF) is an extreme condition after severe acute exacerbation of chronic hepatitis 
B. Tan et al. carried out a genome-wide association study, among 1300 ACLFs and 2087 AsCs, 
and identified rs3129859 at HLA class II region (chromosome 6p21.32) which is associated 
with HBV-related ACLF. Analysis identified HLA-DRB1*12:02 as the top susceptible HLA 
allele associated with ACLF. The association of rs3129859 was robust in ACLF subgroups 
or HBV e antigen-negative chronic hepatitis B phase. Clinical traits analysis in patients with 
ACLF showed that the risky rs3129859*C allele was also associated with prolonged pro-
thrombin time, faster progression to ascites development, and higher 28-day mortality [35]. 
SNP rs9272105 locates between HLA-DQA1 and HLA-DRB1 on 6p21.32. SNP imputation in 
the GWAS discovery samples revealed additional SNPs showing association, but rs9272105 
remained the top SNP within the region [41], which successfully validated the associations 
between rs9272105 and HCC risk [42]. Of the 12 SNPs reported in HBV-related HCC GWASs, 
rs2647073 and rs3997872 near HLA-DRB1 were found to be significantly associated with the 
risk of HBV-related LC, which suggested that genetic variants associated with HBV-related 
hepatocarcinogenesis may already play an important role in the progression from CHB to 
LC [43]. A recent study reported new SNPs at HLA-DRB1 (rs35445101) associated with TP53 
expression status in HBV-related hepatocellular carcinoma [30].
In 2013, Jiang et al. first found the association of HCC risk with rs9275319 at 6p21.3 located 
between HLA-DQB1 and HLA-DQA2, which was not reported in earlier GWASs of HCC [44]. 
Their following research and that of Wen et al. successfully validated the associations between 
rs9275319 and HCC risk [42, 43]. Three SNPs belonging to the HLA-DQ region (rs2856718, 
rs7453920, and rs9275572) were studied. HLA-DQ rs2856718G, rs7453920A, and rs9275572A 
were strongly associated with decreased risk of chronic HBV infection and natural clearance; 
while rs2856718A, rs7453920G, and rs9275572G served as a risk factor in HBV infection in 
Japanese populations and in Southeast China [45–48]. Chang et al. found that rs9276370 
(HLA-DQA2), rs7756516, and rs7453920 (HLA-DQB2) are significantly associated with persis-
tent HBV infection, especially the “T-T” haplotype composed of rs7756516 and rs9276370 that 
is more prevalent in severe disease subgroups and associated with nonsustained therapeutic 
response in male Taiwan Han Chinese individuals [49]. A nearest study reported four new 
SNPs at HLA-DQB1 (rs1130399, rs1049056, rs1049059, and rs1049060) associated with TP53 
expression status in HBV-related HCC [30].
A Chinese study by Zhu et al. [40] identified HLA-DPβ1 positions 84–87 that indepen-
dently drive chronic HBV infection. In 2009, Kamatani et al. first reported two SNPs with 
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the strongest relation to HBV infection from the HLA-DP locus: rs3077 on HLA DPA1 and 
rs9277535 on HLA DPB1 in Japanese and Thai populations [50, 51]. Subsequently, plenty of 
studies further demonstrated their roles [27, 52–54]. rs3077 and rs9277535 are significantly 
related to HBV persistent infection and both A alleles of these two SNPs are protection alleles 
in Chinese Han [55], Japanese and Korean [56], and European [57] populations, while in 
Chinese Zhuang subjects, only HLA-DP rs9277535A is associated with decreased risk [55]. 
Also, only a highly significant association of HLA-DPA1 rs3077C with HBV infection was 
observed in Caucasians [58]. HBeAg-negative HBV carriers with rs9277535 non-GG genotype 
had a higher chance to clear HBsAg. Compared to GG haplotype of rs3077 and rs9277535, 
GA haplotype had a higher chance of achieving spontaneous HBsAg loss in Chinese subjects 
of Taiwan [59]. On the whole, the present findings show that SNPs rs3077 and rs9277535 at 
HLA-DP locus protect against HBV infection and increase the chance of HBV clearance, while 
the importance of these polymorphisms as a predictor of HCC may be limited [45, 60, 61]. In a 
report by Hu et al., HLA-DP rs3077 showed an approaching significant effect on susceptibility 
to HBV persistent infection and HCC development when considering multiple testing adjust-
ments [62]. Li et al. found evidence for the association at rs9277535 with HCC independently 
by imputation [41]. Thomas et al. reported that SNPs rs3077 and rs9277535 that associated 
most significantly with chronic hepatitis B and outcomes of HBV infection in Asians had a 
marginal effect on HBV recovery in European and African-American samples. However, they 
identified a novel variant in the HLA-DPB1 3′UTR region, 496A/G (rs9277534), which associ-
ated very significantly with HBV recovery in both European and African-American popula-
tions [63]. Hu et al. also found that the variant at rs9277534 could affect both the spontaneous 
clearance of HBV infection and progression from asymptomatic HBV carriers to HBV-related 
liver cirrhosis in southwest Han Chinese population [64]. Chang et al. found that rs9366816 
near HLA-DPA3 are significantly associated with persistent HBV infection in male Taiwan 
Han Chinese individuals [49]. A nearest study reported a new SNP at HLA-DPB1 (rs1042153) 
associated with TP53 expression status in HBV-related hepatocellular carcinoma [30].
2.3. The role and mechanism of HLA class II gene variations associated with HBV 
infection outcomes
HLA class II genes encode proteins expressed on the surface of antigen-presenting cells such 
as macrophages, dendritic cells, and B cells, and thereby have a critical role in the presenta-
tion of antigens to CD4+ T-helper lymphocytes. In our previous review, there were three 
mechanisms related to HBV infection outcomes, including HLA molecular structure, HLA 
gene expression, and its regulatory [26].
HLA class II genes have many structural variants that have been linked to immune response 
[65, 66] to autoimmune diseases [67, 68], idiosyncratic drug toxicity (IDT) [69, 70], and infectious 
agents [71, 72]. But the structural variants related to HBV infection outcomes in HLA class II 
genes only have our previous research report [73]. We know that the HLA class II molecules are 
heterodimetric glycoproteins, which are able to present peptides to CD4+ T cells; the primary 
protein sequences (α1 and β1 chains) encoded by the second exon of the HLA class II genes com-
prise the peptide-binding grooves that accommodate amino acid chains of the bound peptides; 
the specificity of the peptide-binding grooves is governed by the properties of pockets in the 
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grooves which include nine different structural pockets (Ps) from P1 to P9, typical pockets being 
P1, P4, P6, and P9, which accommodate the antigen peptide side chains; and the polymorphic 
residues encoded by polymorphic HLA class II genes can influence the structural (size and 
shape) and electrostatic properties and further function of the pockets. So, the determination of 
the structural and electrostatic properties of the HLA class II peptide-binding grooves associ-
ated with diseases may help identify the disease mechanism. We found that DR07 and DR12 
carry amino acids Leu and His at residue 30 of HLA-DRβ1 chain, respectively, and Val at residue 
57 of HLA-DRβ1 chain, difference from Tyr30 and Asp57 carried by DR04 and DR11, leading to 
present positive charge at P9 [73], as well as increasing size due to the absence of an intact salt 
bridge at P6 and P9 [73, 74]. Hence, which HLA DR07 and DR12 is sufficient to chronic HBV 
infection is supported by the structure characters resulting from HLA gene polymorphism.
Gene expression, that is, the qualitative and quantitative expression of mRNA transcripts 
from DNA templates, forms a first link in the functional path between nucleotide sequence 
and higher-order organismal phenotypes. Despite the undeniable importance of a controlled 
gene regulatory process in which proper transcripts are expressed at the correct time and 
location, studies have shown that there is widespread inter-individual variability with respect 
to gene expression, or mRNA levels, within a given cell type or tissue [75]. Early in 1986, 
Edwards et al. [76] examined frozen sections of human fetal spleen from 12 to 20 weeks of 
gestation by using polyclonal antibodies to Ig isotypes, monoclonal antibodies to HLA class II 
subregion locus products, B and T cells, and follicular dendritic cells. Their data suggest that 
class II antigens are differentially expressed on developing lymphoid cells; DR and DP expres-
sion occurring in the earliest spleens examined, with expression of DP on a subpopulation of 
DR-positive cells; IgD and DQ expression appears to be coincident on maturing B cells as they 
begin to form follicles, and an immunoregulatory role for HLA-DQ in B cell development is 
implicated. In fact, HLA class II gene (HLA-DR) expression level is still one of the markers for 
immune reaction related to disease [33, 77]. In 2017, we reviewed the association of HLA-DR 
expression level with diseases and reported our studies about the characteristics of HLA-DR 
expression in patients with different outcomes of HBV infection. Compared to persons with 
no HBV marker, HBV infection and vaccination induce increased expression of HLA-DR, 
especially in the clearance of HBV infection [78]. Genetic variants that influence HLA mRNA 
expression might also affect antigen presentation and many “gene expression-associated 
SNPs” (eSNPs) have been found for HLA genes [79, 80]. An integrated approach combining 
genotype information with genome-wide gene expression data in relevant tissues can identify 
genetic variations that are both regulatory and disease causing [81]. Cavalli et al. believed that 
a majority of causal genetic variants underlying complex diseases appear to involve regu-
latory elements, rather than coding variations [82]. Kaur et al. reported that structural and 
regulatory diversity shape HLA-C protein expression levels and that quantitative variation 
in the expression of HLA-C can influence the clinical course of HIV infection and the risk of 
graft-versus-host disease [83]. By influencing HLA mRNA expression, rs3077 and rs9277535 
variants, both are noncoding variation (3′UTR) in the HLA-DPA1 and HLA-DPB1 region, and 
are related to enhanced clearance of hepatitis B virus infection [57, 63] and increased risk 
of graft-versus-host disease in mismatched hematopoietic cell transplant recipients [84, 85]. 
These findings were identified by a study about mapping of hepatic expression quantitative 
trait loci (eQTLs) in a Han Chinese population by Wang et al. [86].
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the strongest relation to HBV infection from the HLA-DP locus: rs3077 on HLA DPA1 and 
rs9277535 on HLA DPB1 in Japanese and Thai populations [50, 51]. Subsequently, plenty of 
studies further demonstrated their roles [27, 52–54]. rs3077 and rs9277535 are significantly 
related to HBV persistent infection and both A alleles of these two SNPs are protection alleles 
in Chinese Han [55], Japanese and Korean [56], and European [57] populations, while in 
Chinese Zhuang subjects, only HLA-DP rs9277535A is associated with decreased risk [55]. 
Also, only a highly significant association of HLA-DPA1 rs3077C with HBV infection was 
observed in Caucasians [58]. HBeAg-negative HBV carriers with rs9277535 non-GG genotype 
had a higher chance to clear HBsAg. Compared to GG haplotype of rs3077 and rs9277535, 
GA haplotype had a higher chance of achieving spontaneous HBsAg loss in Chinese subjects 
of Taiwan [59]. On the whole, the present findings show that SNPs rs3077 and rs9277535 at 
HLA-DP locus protect against HBV infection and increase the chance of HBV clearance, while 
the importance of these polymorphisms as a predictor of HCC may be limited [45, 60, 61]. In a 
report by Hu et al., HLA-DP rs3077 showed an approaching significant effect on susceptibility 
to HBV persistent infection and HCC development when considering multiple testing adjust-
ments [62]. Li et al. found evidence for the association at rs9277535 with HCC independently 
by imputation [41]. Thomas et al. reported that SNPs rs3077 and rs9277535 that associated 
most significantly with chronic hepatitis B and outcomes of HBV infection in Asians had a 
marginal effect on HBV recovery in European and African-American samples. However, they 
identified a novel variant in the HLA-DPB1 3′UTR region, 496A/G (rs9277534), which associ-
ated very significantly with HBV recovery in both European and African-American popula-
tions [63]. Hu et al. also found that the variant at rs9277534 could affect both the spontaneous 
clearance of HBV infection and progression from asymptomatic HBV carriers to HBV-related 
liver cirrhosis in southwest Han Chinese population [64]. Chang et al. found that rs9366816 
near HLA-DPA3 are significantly associated with persistent HBV infection in male Taiwan 
Han Chinese individuals [49]. A nearest study reported a new SNP at HLA-DPB1 (rs1042153) 
associated with TP53 expression status in HBV-related hepatocellular carcinoma [30].
2.3. The role and mechanism of HLA class II gene variations associated with HBV 
infection outcomes
HLA class II genes encode proteins expressed on the surface of antigen-presenting cells such 
as macrophages, dendritic cells, and B cells, and thereby have a critical role in the presenta-
tion of antigens to CD4+ T-helper lymphocytes. In our previous review, there were three 
mechanisms related to HBV infection outcomes, including HLA molecular structure, HLA 
gene expression, and its regulatory [26].
HLA class II genes have many structural variants that have been linked to immune response 
[65, 66] to autoimmune diseases [67, 68], idiosyncratic drug toxicity (IDT) [69, 70], and infectious 
agents [71, 72]. But the structural variants related to HBV infection outcomes in HLA class II 
genes only have our previous research report [73]. We know that the HLA class II molecules are 
heterodimetric glycoproteins, which are able to present peptides to CD4+ T cells; the primary 
protein sequences (α1 and β1 chains) encoded by the second exon of the HLA class II genes com-
prise the peptide-binding grooves that accommodate amino acid chains of the bound peptides; 
the specificity of the peptide-binding grooves is governed by the properties of pockets in the 
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grooves which include nine different structural pockets (Ps) from P1 to P9, typical pockets being 
P1, P4, P6, and P9, which accommodate the antigen peptide side chains; and the polymorphic 
residues encoded by polymorphic HLA class II genes can influence the structural (size and 
shape) and electrostatic properties and further function of the pockets. So, the determination of 
the structural and electrostatic properties of the HLA class II peptide-binding grooves associ-
ated with diseases may help identify the disease mechanism. We found that DR07 and DR12 
carry amino acids Leu and His at residue 30 of HLA-DRβ1 chain, respectively, and Val at residue 
57 of HLA-DRβ1 chain, difference from Tyr30 and Asp57 carried by DR04 and DR11, leading to 
present positive charge at P9 [73], as well as increasing size due to the absence of an intact salt 
bridge at P6 and P9 [73, 74]. Hence, which HLA DR07 and DR12 is sufficient to chronic HBV 
infection is supported by the structure characters resulting from HLA gene polymorphism.
Gene expression, that is, the qualitative and quantitative expression of mRNA transcripts 
from DNA templates, forms a first link in the functional path between nucleotide sequence 
and higher-order organismal phenotypes. Despite the undeniable importance of a controlled 
gene regulatory process in which proper transcripts are expressed at the correct time and 
location, studies have shown that there is widespread inter-individual variability with respect 
to gene expression, or mRNA levels, within a given cell type or tissue [75]. Early in 1986, 
Edwards et al. [76] examined frozen sections of human fetal spleen from 12 to 20 weeks of 
gestation by using polyclonal antibodies to Ig isotypes, monoclonal antibodies to HLA class II 
subregion locus products, B and T cells, and follicular dendritic cells. Their data suggest that 
class II antigens are differentially expressed on developing lymphoid cells; DR and DP expres-
sion occurring in the earliest spleens examined, with expression of DP on a subpopulation of 
DR-positive cells; IgD and DQ expression appears to be coincident on maturing B cells as they 
begin to form follicles, and an immunoregulatory role for HLA-DQ in B cell development is 
implicated. In fact, HLA class II gene (HLA-DR) expression level is still one of the markers for 
immune reaction related to disease [33, 77]. In 2017, we reviewed the association of HLA-DR 
expression level with diseases and reported our studies about the characteristics of HLA-DR 
expression in patients with different outcomes of HBV infection. Compared to persons with 
no HBV marker, HBV infection and vaccination induce increased expression of HLA-DR, 
especially in the clearance of HBV infection [78]. Genetic variants that influence HLA mRNA 
expression might also affect antigen presentation and many “gene expression-associated 
SNPs” (eSNPs) have been found for HLA genes [79, 80]. An integrated approach combining 
genotype information with genome-wide gene expression data in relevant tissues can identify 
genetic variations that are both regulatory and disease causing [81]. Cavalli et al. believed that 
a majority of causal genetic variants underlying complex diseases appear to involve regu-
latory elements, rather than coding variations [82]. Kaur et al. reported that structural and 
regulatory diversity shape HLA-C protein expression levels and that quantitative variation 
in the expression of HLA-C can influence the clinical course of HIV infection and the risk of 
graft-versus-host disease [83]. By influencing HLA mRNA expression, rs3077 and rs9277535 
variants, both are noncoding variation (3′UTR) in the HLA-DPA1 and HLA-DPB1 region, and 
are related to enhanced clearance of hepatitis B virus infection [57, 63] and increased risk 
of graft-versus-host disease in mismatched hematopoietic cell transplant recipients [84, 85]. 
These findings were identified by a study about mapping of hepatic expression quantitative 
trait loci (eQTLs) in a Han Chinese population by Wang et al. [86].
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eQTLs, namely, the discovery of genetic variants, explain variation in gene expression levels 
which has significant differences in mean expression levels between population, tissue or cell 
type [75, 87]. Typically, in the eQTL mapping literature, regulatory variants have been charac-
terized as either cis or trans acting, reflecting the predicted nature of interactions and of course 
depending on the physical distance from the gene they regulate. Conventionally, variants within 
1–2 Mb (megabase) on either side of a gene’s TSS were called cis, while those at least 5 Mb 
downstream or upstream of the TSS or on a different chromosome were considered trans act-
ing [87]. The most significant GWAS SNPs are strong eQTLs and proposing candidate disease 
genes. Multiple variants of low-effect sizes affect multiple genes by gene regulatory network. 
A network component can be viewed as a cis effect that transmits its signal in trans essentially 
making the cis SNP a trans SNP as well [87]. Such studies have offered promise not just for 
the characterization of functional sequence variation but also for the understanding of basic 
processes of gene regulation and interpretation of genome-wide association studies [75, 87].
Up to now, many research findings have demonstrated that HLA class II gene variations, 
including allele polymorphisms and SNPs, are associated with HBV infection outcomes 
by influencing the molecular structure and the expression level of HLA class II molecules 
expressed on the cell surface. As the researches progress with methodological improvements, 
such as the prediction of gene expression [88] and PrediXcan analysis [89], more structure 
variations, cis SNPs and trans SNPs, were found underlying this disease. This can help under-
stand the mechanisms linking genome-wide association loci to the disease, and implement 
precise individualized prevention, diagnosis, and treatment of the disease.
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